

A Bayesian Mixture Modelling Approach For Spatial Proteomics

Oliver M. Crook^{1,2,3}, Claire M. Mulvey², Paul D.W. Kirk³, Kathryn S. Lilley², and Laurent Gatto*^{1,2,4,*}

¹ *Computational Proteomics Unit, Department of Biochemistry, University of Cambridge, Cambridge, UK*

² *Cambridge Centre for Proteomics, Department of Biochemistry, University of Cambridge, Cambridge, UK*

³ *MRC Biostatistics Unit, Cambridge Institute for Public Health, Cambridge, UK*

⁴ *Current address: de Duve Institute, UCLouvain, Avenue Hippocrate 75, 1200 Brussels, Belgium*

October 5, 2018

Abstract

Analysis of the spatial sub-cellular distribution of proteins is of vital importance to fully understand context specific protein function. Some proteins can be found with a single location within a cell, but up to half of proteins may reside in multiple locations, can dynamically re-localise, or reside within an unknown functional compartment. These considerations lead to uncertainty in associating a protein to a single location. Currently, mass spectrometry (MS) based spatial proteomics relies on supervised machine learning algorithms to assign proteins to sub-cellular locations based on common gradient profiles. However, such methods fail to quantify uncertainty associated with sub-cellular class assignment. Here we reformulate the framework on which we perform statistical analysis. We propose a Bayesian generative classifier based on Gaussian mixture models to assign proteins probabilistically to sub-cellular niches, thus proteins have a probability distribution over sub-cellular locations, with Bayesian computation performed using the expectation-maximisation (EM) algorithm, as well as Markov-chain Monte-Carlo (MCMC). Our methodology allows proteome-wide uncertainty quantification, thus adding a further layer to the analysis of spatial proteomics. Our framework is flexible, allowing many different systems to be analysed and reveals new modelling opportunities for spatial proteomics. We find our methods perform competitively with current state-of-the art machine learning methods, whilst simultaneously providing more information. We highlight several examples where classification based on the support vector machine is unable to make any conclusions, while uncertainty quantification using our approach provides biologically intriguing results. To our knowledge this is the first Bayesian model of MS-based spatial proteomics data.

*laurent.gatto@uclouvain.be

Author summary

Sub-cellular localisation of proteins provides insights into sub-cellular biological processes. For a protein to carry out its intended function it must be localised to the correct sub-cellular environment, whether that be organelles, vesicles or any sub-cellular niche. Correct sub-cellular localisation ensures the biochemical conditions for the protein to carry out its molecular function are met, as well as being near its intended interaction partners. Therefore, mis-localisation of proteins alters cell biochemistry and can disrupt, for example, signalling pathways or inhibit the trafficking of material around the cell. The sub-cellular distribution of proteins is complicated by proteins that can reside in multiple micro-environments, or those that move dynamically within the cell. Methods that predict protein sub-cellular localisation often fail to quantify the uncertainty that arises from the complex and dynamic nature of the sub-cellular environment. Here we present a Bayesian methodology to analyse protein sub-cellular localisation. We explicitly model our data and use Bayesian inference to quantify uncertainty in our predictions. We find our method is competitive with state-of-the-art machine learning methods and additionally provides uncertainty quantification. We show that, with this additional information, we can make deeper insights into the fundamental biochemistry of the cell.

1 Introduction

Spatial proteomics is an interdisciplinary field studying the localisation of proteins on a large-scale. Where a protein is localised in a cell is a fundamental question, since a protein must be localised to its required sub-cellular compartment to interact with its binding partners (for example, proteins, nucleic acids, metabolic substrates) and carry out its function (Gibson, 2009). Furthermore, mis-localisations of proteins are also critical to our understanding of biology, as aberrant protein localisation have been implicated in many pathologies (Olkkonen and Ikonen, 2006; Luheshi *et al.*, 2008; Laurila and Vihinen, 2009; De Matteis and Luini, 2011; Cody *et al.*, 2013), including cancer (Kau *et al.*, 2004; Rodriguez *et al.*, 2004; Latorre *et al.*, 2005; Shin *et al.*, 2013) and obesity (Siljee *et al.*, 2018).

Sub-cellular localisations of proteins can be studied by high-throughput mass spectrometry (MS) (Gatto *et al.*, 2010). MS-based spatial proteomics experiments enable us to confidently determine the sub-cellular localisation of thousands of proteins within in a cell (Christoforou *et al.*, 2016), given the availability of rigorous data analysis and interpretation (Gatto *et al.*, 2010).

In a typical MS-based spatial proteomics experiment, cells first undergo lysis in a fashion which maintains the integrity of their organelles. The cell content is then separated using a variety of methods, such as density separation (Dunkley *et al.*, 2006; Christoforou *et al.*, 2016), differential centrifugation (Itzhak *et al.*, 2016), free-flow electrophoresis (Parsons *et al.*, 2014), or affinity purification (Heard *et al.*, 2015). In LOPIT (Dunkley *et al.*, 2004, 2006; Sadowski *et al.*, 2006) and *hyper*LOPIT (Christoforou *et al.*, 2016; Mulvey *et al.*, 2017), cell lysis is proceeded by separation of the content along a density gradient. Organelles and macro-molecular complexes are thus characterised by density-specific profiles along the gradient (De Duve and Beaufay, 1981). Discrete fractions along the continuous density

gradient are then collected, and quantitative protein profiles that match the organelle profiles along the gradient, are measured using high accuracy mass spectrometry (Mulvey *et al.*, 2017).

The data are first visualised using principal component analysis (PCA) and known sub-cellular compartments are annotated (Breckels *et al.*, 2016a). Supervised machine learning algorithms are then typically employed to create classifiers that associate un-annotated proteins to specific organelles (Gatto *et al.*, 2014a), as well as semi-supervised methods that detect novel sub-cellular clusters using both labelled and un-labelled features (Breckels *et al.*, 2013). More recently, a state-of-the-art transfer learning (TL) algorithm has been shown to improve the quantity and reliability of sub-cellular protein assignments (Breckels *et al.*, 2016b). Applications of such methods have led to organelle-specific localisation information of proteins in plants (Dunkley *et al.*, 2006), *Drosophila* (Tan *et al.*, 2009), chicken (Hall *et al.*, 2009), human cell lines (Breckels *et al.*, 2013), mouse pluripotent embryonic stem cells (Christoforou *et al.*, 2016) and cancer cell lines (Thul *et al.*, 2017).

Classification methods which have previously been used include partial least squares discriminate analysis (Dunkley *et al.*, 2006), K nearest neighbours (Groen *et al.*, 2014), random forests (Ohta *et al.*, 2010), naive Bayes (Nikolovski *et al.*, 2012), neural networks (Tardif *et al.*, 2012) and the support vector machine amongst others (see Gatto *et al.* (2014a) for an overview). Although these methods have proved successful within the field they have limitations. Typically, such classifiers output an assignment of proteins to discrete pre-annotated sub-cellular locations. However, it is important to note that half the proteome cannot be robustly assigned to a single sub-cellular location, which may be a manifestation of proteins in so far uncharacterised organelles or proteins that are distributed amongst multiple locations. These factors lead to uncertainty in the assignment of proteins to sub-cellular localisations, and thus quantifying this uncertainty is of vital importance (Kirk *et al.*, 2015).

To overcome the task of uncertainty quantification, this article presents a probabilistic generative model for MS-based spatial proteomics data. Our model posits that each annotated sub-cellular niche can be modelled by a multivariate Gaussian distribution. Thus, the full complement of annotated proteins is captured by a mixture of multivariate Gaussian distributions. With the prior knowledge that many proteins are not captured by known sub-cellular niches, we augment our model with an outlier component. Outliers are often dispersed and thus this additional component is described by a heavy-tailed distribution: the multivariate Student’s t-distribution, leading us to a T Augmented Gaussian Mixture model (TAGM).

Given our model and proteins with known location, we can probabilistically infer the sub-cellular localisation of thousands of proteins. We can perform inference in our model by finding *maximum a posteriori* (MAP) estimates of the parameters. This approach returns the probability of each protein belonging to each annotated sub-cellular niche. These posterior localisation probabilities can then be the basis for classification. In a more sophisticated, fully Bayesian approach to uncertainty quantification, we can additionally infer the entire posterior distribution of localisation probabilities. This allows the uncertainty in the parameters in our model to be reflected in the posterior localisation probabilities. We perform this inference using Markov-chain Monte-Carlo methods; in particular, we provide an efficient collapsed Gibbs sampler to perform inference.

We perform a comprehensive comparison to state-of-the-art classifiers to demonstrate

that our method is reliable across 19 different spatial proteomics datasets and find that all classifiers we considered perform competitively. To demonstrate the additional biological advantages our method can provide, we apply our method to a *hyper*LOPIT dataset on mouse pluripotent embryonic stem cells (Christoforou *et al.*, 2016). We consider several examples of proteins that were unable to be assigned using traditional machine-learning classifiers and show that, by considering the full posterior distribution of localisation probabilities, we can draw meaningful biological results and make powerful conclusions. We then turn our hand to a more global perspective, visualising uncertainty quantification for over 5,000 proteins, simultaneously. This approach reveals global patterns of protein organisation and their distribution across sub-cellular compartments.

We make extensive use of the R programming language (R Core Team, 2017) and existing MS and proteomics packages (Gatto and Lilley, 2012; Gatto *et al.*, 2014b). We are highly committed to creating open software tools for high quality processing, visualisation, and analysis of spatial proteomics data. We build upon an already extensive set of open software tools (Gatto *et al.*, 2014b) as part of the Bioconductor project (Gentleman *et al.*, 2004; Huber *et al.*, 2015) and our methods are made available as part of this project.

2 Results

2.1 Application to mouse pluripotent embryonic stem cell data

We model mouse pluripotent embryonic stem cell (E14TG2a) data (Christoforou *et al.*, 2016), which contains quantitation data for 5032 proteins. This high-resolution map was produced using the *hyper*LOPIT workflow (Mulvey *et al.*, 2017), which uses a sophisticated sub-cellular fractionation scheme. This fractionation scheme is made possible by the use of Tandem Mass Tag (TMT) 10-plex and high accuracy TMT quantification was facilitated by using synchronous precursor selection MS3 (SPS-MS3) (McAlister *et al.*, 2014), which reduces well documented issues with ratio distortion in isobaric multiplexed quantitative proteomics (Ting *et al.*, 2011). The data resolves 14 sub-cellular niches with an additional chromatin preparation resolving the nuclear chromatin and non-chromatin components. Two biological replicates of the data are concatenated, each with 10 fractions along the density gradient. We defined gold standard organelle markers as those with unambiguous single annotation (Gatto *et al.*, 2014a). A protein marker list for the mouse pluripotent embryonic stem cells was manually curated using information from the UniProt database, the Gene Ontology and the literature, as was performed in Christoforou *et al.* (2016). The following section applies our statistical methodology to these data and we explore the results.

2.1.1 Maximum a posteriori prediction of protein localisation

This section applies the TAGM model to the mouse pluripotent embryonic stem cell data, by deriving MAP estimates for the model parameters and using these for prediction. Visualisation is important for data analysis and exploration. A simple way to visualise our model is to project probability ellipses onto a PCA plot. Each ellipse contains a proportion of total probability of a particular multivariate Gaussian density. The outer ellipse contains 99% of

the total probability whilst the middle and inner ellipses contain 95% and 90% of the probability respectively. Visualising only the first two principal components can be misleading, since proteins can be more (or less) separated in subsequent principal components. We visualise the first two principal components along with the first and fourth principal components as a representative example. For the TAGM model, we derive probability ellipses from the MAP estimates of the parameters.




Figure 1: (a) PCA plot of the 1st and 2nd principal components for the curated marker proteins of the mouse stem cell data. The organelles are, in general, well separated. Though some organelles overlap, they are separated along different principal components. The densities used to produce the ellipses are derived from the MAP estimates. (b) Marker resolution along the 1st and 4th principal components show that the mitochondrion and peroxisome markers are well resolved, despite overlapping in the 1st and 2nd component. We also see that the ER/Golgi apparatus markers are better separated from the extracellular matrix markers.

We now apply the statistical methodology described in section 4, to predict the localisation of proteins to organelles and sub-cellular components. In brief, we produce MAP estimates of the parameters by using the expectation-maximisation algorithm, to form the basis of a Bayesian analysis (TAGM-MAP). We run the algorithm for 200 iterations and inspect a plot of the log-posterior to assess convergence of the algorithm (see appendix 5.3). We confirm that the difference of the log posterior between the final two iterations is less than 10^{-6} and we conclude that our algorithm has converged. The results can be seen in figure 2 (left), where the posterior localisation probability is visualised by scaling the pointer for each protein.

Figure 2 (right) demonstrates a range of probabilistic assignments of proteins to organelles and sub-cellular niches. We additionally consider a full, sampling-based Bayesian analysis using Markov-chain Monte Carlo (MCMC) to characterise the uncertainty in the localisation

probabilities. In our case a collapsed Gibbs sampler is used to sample from the posterior of localisation probabilities. The remainder of this article focus on analysis of spatial proteomics in this fully Bayesian framework.




Figure 2: PCA plot of the protein quantitation data with colours representing the predicted class (5032 proteins) illustrating protein localisation predictions using TAGM-MAP (left) and TAGM-MCMC (right) respectively. The pointer size of a protein is scaled to the probability that particular protein was assigned to that organelle. Markers, proteins whose localisations are already known, are automatically assigned a probability of 1 and the size of the pointer reflects this.

2.1.2 Uncertainty in the posterior localisation probabilities

This section applies the TAGM model to the mouse pluripotent embryonic stem cell data, by considering the uncertainty in the parameters and exploring how this uncertainty propagates to the uncertainty in protein localisation prediction. In figure 3 we visualise the model as before using the first two principal components along with the first and fourth principal component as a representative example. For the TAGM model, we derive probability ellipses from the expected value of the posterior normal-inverse-Wishart (NIW) distribution.

We apply the statistical methodology detailed in section 4. We perform posterior computation in the Bayesian setting using standard MCMC methods (TAGM-MCMC). We run 6 chains of our Gibbs sampler in parallel for 15,000 iterations, throwing away the first 4,000 iterations for burn-in and retain every 10th sample for thinning. Thus 1,100 sample are retained from each chain. We then visualise the trace plots of our chains; in particular, we monitor the number of proteins allocated to the known components (see appendix 5.4). We discard 1 chain because we do not consider it to have converged. For the remaining 5 chains we further discard the first 500 samples by visual inspection. We then have 600 retained

185 samples from 5 separate chains. For further analysis, we compute the Gelman-Rubin conver-
 186 gence diagnostic (Gelman and Rubin, 1992; Brooks and Gelman, 1998), which is computed
 187 as $\hat{R} \approx 1.05$. Values of \hat{R} far from 1 indicate non-convergence and since our statistic is less
 188 than 1.1, we conclude our chains have converged. The remaining samples are then pooled to
 189 produce a single chain containing 3000 samples.

190 We produce point estimates of the posterior localisation probabilities by summarising
 191 samples by their Monte-Carlo average. These summaries are then visualised in figure 2
 192 (right panel), where the pointer is scaled according to the localisation probabilities of the
 193 sub-cellular niche with the largest posterior probability. Monte-Carlo based inference also
 194 provides us with additional information; in particular, we can interrogate individual proteins
 195 and their posterior probability distribution over sub-cellular locations.

196 Figure 4 illustrates one example of the importance of capturing uncertainty. The E3
 197 ubiquitin-protein ligase TRIP12 (G5E870) is an integral part of ubiquitin fusion degrada-
 198 tion pathway and is a protein of great interest in cancer because it regulates DNA repair
 199 pathways. The SVM failed to assign this protein to any location, with assignment to the 60S
 200 Ribosome falling below a 5% FDR and the MAP estimate assigned the protein to the nucleus
 201 non-chromatin with posterior probability < 0.95 . The posterior distribution of localisation
 202 probabilities inferred from the TAGM-MCMC model, shown in figure 4, demonstrates that
 203 this protein is most probably localised to the nucleus non-chromatin. However, there is some
 204 uncertainty about whether it localises to the 40S ribosome. This could suggest a dynamic
 205 role for this protein, which could be further explored with a more targeted experiment.




Figure 3: (a) Probability ellipses produced from using the MCMC method. The density is the expected value from the NIW distribution. (b) Probability ellipses visualised along the 1st and 4th principal component also from the MCMC method.




Figure 4: Violin plot revealing the posterior distribution of localisation probabilities of protein E3 ubiquitin-protein ligase (G5E870) to organelles and sub-cellular niches. The most probable localisation is nucleus non-chromatin, however there is uncertainty associated with this assignment.

2.1.3 Enrichment analysis of outlier proteins

In previous sections, we demonstrated that we can assign proteins probabilistically to sub-cellular compartment and quantify the uncertainty in these assignments. Some proteins cannot be well described as belonging to any known component and we model this using an additional T-distribution outlier component (see Section 4).

It is biologically interesting to decipher what functional role proteins that are far away from known components play. We perform an over-representation analysis of gene ontology (GO) terms to assess the biological relevance of the outlier component (Boyle *et al.*, 2004; Yu *et al.*, 2012). We take 1111 proteins that were allocated to known components with probability less than 0.95. Note that these 1111 proteins exclude proteins that are likely to belong to a known location, but we are uncertain about which localisation. We then perform enrichment analysis against the set of all proteins quantified in the *hyper*LOPIT experiment. We search against the cellular compartment, biological process and molecular function ontologies.

Supplementary figure 16 shows this outlier component is enriched for cytoskeletal part ($p < 10^{-7}$) and microtubule cytoskeleton ($p < 10^{-7}$). Cytoskeleton proteins are found throughout the cell and therefore we would expect them to be found in every fraction along the density gradient. We also observe enrichment for highly dynamic sub-cellular processes such as cell division ($p < 10^{-6}$) and cell cycle processes ($p < 10^{-6}$), again these proteins are unlikely to have steady-state locations within a single component. We also see enrichment for molecular functions such as transferase activity ($p < 0.005$), another highly dynamic process. These observations justify including an additional outlier component in our mixture model.

2.2 Comparison with other classifiers

In this section, we assess the generalisation performance of our methods on several datasets, by computing performance metrics associated with each classifier as detailed in section 4.4. We compare the SVM and KNN classifiers alongside the MAP and MCMC approaches detailed in the methods section. We compute the F1 score and quadratic loss over 100 rounds of stratified 5-fold cross-validation. The hyperparameter for the KNN algorithm, the number of nearest neighbours, is optimised via an additional internal 5-fold cross-validation and the hyperparameters for the SVM, sigma and cost, are also optimised via internal 5-fold cross validation (Hsu *et al.*, 2010).

We test our methods on the following datasets *Drosophila* (Tan *et al.*, 2009), chicken (Hall *et al.*, 2009), mouse pluripotent embryonic stem cells from Christoforou *et al.* (2016) and Breckels *et al.* (2016b), the human bone osteosarcoma epithelial (U2-OS) cell line (Thul *et al.*, 2017), the HeLa cell line of Itzhak *et al.* (2016), the 3 HeLa cell lines from Hirst *et al.* (2018) and 10 primary fibroblast datasets from Beltran *et al.* (2016). These datasets represent a great variety of spatial proteomics experiments across many different workflows.

The two *hyper*LOPIT datasets on mouse pluripotent embryonic stem cells and the U2-OS cell line use TMT 10-plex labelling and contain the greatest number of proteins. Earlier LOPIT experiments on the *Drosophila* and chicken use iTRAQ 4-plex labelling, whilst another LOPIT mouse pluripotent embryonic stem cell dataset uses iTRAQ 8-plex. The datasets of Itzhak *et al.* (2016) and Hirst *et al.* (2018) employ a different methodology completely - separating cellular content using differential centrifugation (as opposed to along a density-gradient). Furthermore, the methods use SILAC rather than iTRAQ or TMT for labelling. The experiments of Hirst *et al.* (2018) were designed to explore the functional role of AP-5 by coupling CRISPR-CAS9 knockouts with spatial proteomics methods. We analysed all three datasets from Hirst *et al.* (2018), which includes a wild type HeLa cell line as a control, as well as two CRISPR-CAS9 knockouts: AP5Z1-KO1 and AP5Z1-KO2 respectively.

In addition, we analyse the spatio-temporal proteomics experiments of Beltran *et al.* (2016), which uses TMT-based MS quantification. This experiment explored infecting primary fibroblasts with Human cytomegalovirus (HCMV) and the goal of these experiments was to explore the dynamic perturbation of host proteins during infection, as well as the sub-cellular localisation of viral proteins through the HCMV life-cycle. They produced spatial maps at different time points: 24, 48, 72, 96, 120 hours post infection (hpi), as well as mock maps at these same time points to serve as a control - this results in 10 different spatial proteomics maps.

In each case, a dataset specific marker list was used, which is curated specifically for the each cell line. We removed "high-curvature ER" annotations from the HeLa dataset (Itzhak *et al.*, 2016), as well as the "ER Tubular", "Nuclear pore complex" and "Peroxisome" annotations from the HeLa CRISPR-CAS9 knockout experiments (Hirst *et al.*, 2018) as there are too few proteins to correctly perform cross-validation. Table 1 summarises these datasets, including information about number of quantified proteins, the workflow used and the number of fractions.

Figure 5 compares the Macro-F1 scores across the datasets for all classifiers and demonstrates that no single classifier consistently outperforms any other across all datasets, with results being highly consistent across all methods, as well as across datasets. We perform

MS-based Spatial Proteomics datasets				
Cell line or organism	Workflow	Labelling	Fractions (including combined replicates)	Proteins
<i>Drosophila</i>	LOPIT	iTRAQ	4	888
Chicken DT40	LOPIT	iTRAQ	16	1090
Mouse pluripotent E14TG2a stem cell	HyperLOPIT	TMT	20	5032
HeLa (Itzhak et al.)	Organeller Maps	SILAC	30	3766
HeLa (Hirst et al.)	Organeller Maps	SILAC	15	2046
U2-OS cell line	HyperLOPIT	TMT	37	5020
Primary Fibroblast	Spatio-Temporal Methods	TMT	6	2196
E14TG2a (Breckels et al.)	LOPIT	iTRAQ	8	2031

Table 1: Summary of spatial proteomics datasets used for comparisons

a pairwise unpaired t-test with multiple testing correction applied using the Benjamini-Höcherberg procedure ([Benjamini and Hochberg, 1995](#)) to detect differences between classifier performance.

In the *Drosophila* dataset only the KNN algorithm outperforms the SVM at significance level of 0.01, whilst no other significant differences exist between the classifiers. In the chicken DT40 dataset only the MCMC method outperforms the KNN classifier at significance level of 0.01, no other significant conclusion can be drawn. In the mouse dataset the MAP based method outperforms the MCMC method at significance level of 0.01, no other significant conclusions can be drawn. In the HeLa dataset all classifiers are significantly different at a 0.01 level. These differences may exist because the dataset does not fit well with our modelling assumptions; in particular, this dataset set has been curated to have a class called "Large Protein Complex", which likely describes several sub-cellular structures. These might include nuclear compartments and ribosomes, as well as any cytosolic complex and large protein complex which pellets during the centrifugation conditions used to capture this mixed sub-cellular fraction. Moreover, the cytosolic and nuclear fraction were processed separately leading to possible imbalance with comparisons with other datasets. Thus, the large protein complex component might be better described as itself a mixture model or more detailed curation of these data may be required. We do not consider further modelling of this dataset in this manuscript. For the U2-OS all classifiers are significantly different at a significance level of 0.01 except for the SVM classifier and the MCMC method, with the MAP

method performing the best. Figure 5 shows that for this dataset all classifiers are performing extremely well. In the three Hirst datasets the MAP method significantly outperforms all other methods ($p < 0.01$), whilst in the wild type HeLa and in the CRISPR-CAS9 KO1 there is no significant difference between the KNN and MCMC method. In the CRISPR-CAS9 KO2 the MCMC method outperforms the SVM and KNN methods ($p < 0.01$). In the interest of brevity, the remaining results for the t-tests can be found in tables in appendix 5.5.




Figure 5: Boxplots of the distributions of Macro F1 scores for all spatial proteomics datasets.

299 The Macro-F1 scores do not take into account that whilst the TAGM model may mis-
300 classify, it may do so with low confidence. We therefore additionally compute the quadratic
301 loss, which allows us to make use of the probabilistic information provided by the classifiers.
302 The lower the quadratic loss the closer the probabilistic prediction is to the true value. We
303 plot the distributions of quadratic losses for each classifier in figure 6. We observe highly
304 consistent performance across all classifiers across all datasets. Again, we perform a pairwise
305 unpaired t-test with multiple testing correction.

306 We find that in 16 out of 19 datasets (all of those except HeLa Wild type, HeLa KO1
307 and HeLa KO2) the MCMC methods achieves the lowest quadratic loss at a significance
308 level < 0.0001 over the SVM and KNN classifiers. In 6 out of these 16 datasets there is no
309 significant difference between the MCMC and the MAP methods. In the three Hirst datasets
310 in which the MCMC did not achieve the lowest quadratic loss, the SVM outperformed.
311 However, in two of these datasets (HeLa Wild type and KO1) the MAP method and SVM
312 classifier were not significantly different. In the Hirst KO2 dataset there were no significant
313 differences between the MAP and MCMC methods.

314 In the vast majority of cases, we observe that if the TAGM model, using the MCMC
315 methodology, makes an incorrect classification it does so with lower confidence than the SVM
316 classifier, the KNN classifier and the MAP based classifier, whilst if it is correct in its assertion
317 it does so with greater confidence. Additionally, a fully Bayesian methodology provides us
318 with not only point estimates of classification probabilities but uncertainty quantification in
319 these allocations, and we show in the following section that this provides deeper insights into
320 protein localisation.




Figure 6: Boxplots of the distributions of Quadratic losses for all spatial proteomics datasets.

Computing distributions of F1 scores and quadratic losses, which can only be done on the marker proteins, can help us understand whether a classifier might have greater generalised performance accuracy. However, we are interested in whether there is a large disagreement between classifiers when prediction is performed on proteins for which we have no withheld localisation information. This informs us about a systematic bias for a particular classifier or whether a classifier ensemble could increase performance. To maintain a common set of proteins we set thresholds for each classifier in turn and compare to the other classifier without thresholding. Firstly, we set a global threshold of 0.95 for the TAGM-MCMC and then for these proteins plot a contingency table against the classification results from the SVM. Secondly, we set a 5% FDR for the SVM and then for these proteins plot a contingency table against the classification results from the TAGM-MCMC. We visualise the contingency tables as heat plots in figure 7.




Figure 7: A heatmap representation of a contingency table, where we compare assignment results for proteins with unknown protein localisation using the TAGM-MCMC and SVM. The scale ranges from 0 to 1 with values indicating the proportion of assigned proteins to that sub-cellular location. Values along the diagonal represent agreement between classifiers whilst other values represent disagreement. The coherence between the classifiers is very high. (a) In this case we set a probability threshold of 0.95 for the TAGM assignments with no threshold for the SVM. (b) In this case we set a 5% FDR threshold for the SVM and no threshold for the TAGM-MCMC.

In general, we see an extremely high level of coherence between the TAGM and the SVM, with almost all proteins predicted to concordant sub-cellular compartments. Figure 7 shows there is some disagreement between assigning proteins to the lysosome and plasma membrane, to the cytosol and proteasome, and between the large and small ribosomal subunits. However, we have not used the uncertainty in the probabilistic assignments to produce the contingency tables above. In the next sections, we explore examples of proteins with uncertainty in their posterior localisation probabilities. Selecting biologically relevant thresholds is important for any classifier and exploring uncertainty is of vital importance when drawing biological conclusions.

2.3 Interpreting and exploring uncertainty

Protein sub-cellular localisation can be uncertain for a number of reasons. Technical variations and unknown biological novelty, such as yet uncharacterised functional compartments, can be some of the reasons why a protein might have an unknown or uncertain localisation. Furthermore many proteins are known to reside in multiple locations with possibly different functional duties in each location (Jeffery, 2009). With these considerations in mind, it is pertinent to quantify the uncertainty in our allocation of proteins to organelles. This section explores several situations where proteins display uncertain localisation and considers the biological factors that influence uncertainty. We later explore and visualise whole proteome uncertainty quantification.

Exportin 5 (Q924C1) forms part of the micro-RNA export machinery of the nucleus, transporting miRNA from the nucleus to the cytoplasm for further processing. It then translocates back through the nuclear pore complex to return to the nucleus. Exportin 5 can then continue to mediate further transport between nucleus and cytoplasm. The SVM was unable to assign a localisation of Exportin 5, with its assignment falling below a 5% FDR to wrongly assign this protein to the proteasome. This incorrect assertion by the SVM was confounded by the similarity between the cytosol and proteasome profiles. Figure 8 demonstrates, according to the TAGM-MCMC model, that Exportin 5 most likely localises to the cytosol but there is some uncertainty with this assignment. This uncertainty is reflected in possible assignment of Exportin 5 to the nucleus non-chromatin and this uncertainty is a manifestation of the fact that the function of this protein is to shuttle between the cytosol and nucleus.

The Phenylalanine-tRNA ligase beta subunit protein (Q9WUA2) has an uncertain localisation between the 40S ribosome and the nucleus non-chromatin demonstrated in figure 9. This protein was left unclassified by the SVM because its score fell below a 5% FDR threshold to assign it to the 40S ribosome. Considering that this protein is involved in the acylation of transfer RNA (tRNA) with the amino acid phenylalanine to form tRNA-Phe to be used in translation of proteins, it is therefore unsurprising that this protein's steady state location is ribosomal. Whilst the SVM is unable to make an assignment, TAGM-MCMC is able to suggest an assignment and quantify our uncertainty.

Relatively little is known about the Dedicator of cytokinesis (DOCK) protein 6 (Q8VDR9), a guanine nucleotide exchange factor for CDC42 and RAC1 small GTPases. The SVM could not assign localisation to the ER/Golgi, since its score fell below a 5% FDR. Furthermore, the TAGM-MCMC model assigned this DOCK 6 to the outlier component with posterior probability > 0.95 . Figure 10 shows possible localisation to several components along the secretory pathway. As an activator for CDC42 and RAC1 we may expect to see them with similar localisation. CDC42, a plasma membrane associated protein, regulates cell cycle and division and is found with many localisations. Furthermore RAC1, a small GTPase, also regulates many cellular processes and is found in many locations. Thus the steady-state distribution of DOCK6 is unlikely to be in a single location, since its interaction partners are found in many locations. This justifies including an outlier component in our model, else we may erroneously assign such proteins to a single location.




Figure 9: Phenylalanine-tRNA ligase beta subunit protein TRIP12 (Q9WUA2) showing localisation to the 40S Ribosome with some uncertainty about association to the nucleus non-chromatin. (a) The violin plot shows uncertain localisation between these two subcellular localisations. (b) The quantitative profile of this protein shows mixed profile between the profiles of the organelle markers. (c) The density plot shows a complex distribution over localisations for this protein. (d) The protein Q9WUA2 has steady state distribution skewed towards the 40S Ribosome and close to the nucleus non-chromatin.




Figure 10: Q8VDR9 showing localisation to the outlier component. (a) The violin plot shows uncertain localisation between several sub-cellular niches. (b) The quantitative profile of this protein shows mixed profile between the profiles of the organelle markers. (c) The density plot shows a similar localisation probabilities for both the ER/Golgi and Extracellular matrix. (d) The protein Q8VDR9 has steady state distribution in the centre of the plot skewed toward the secretory pathway; in particular, the ER/Golgi and Extracellular matrix components.

2.4 Visualising whole sub-cellular proteome uncertainty

The advantage of the TAGM-MCMC model is its ability to provide proteome wide uncertainty quantification. Regions where organelle assignments overlap are areas where uncertainty is expected to be the greatest, as well as areas with no dominant component. We take an information theoretic approach to summarising uncertainty in protein localisation by computing the Shannon entropy (Shannon, 1948) for each Monte-Carlo sample $t = 1, \dots, T$ of the posterior localisation probabilities of each protein

$$\left\{ H^{(t)} = - \sum_{k=1}^K p_{ik}^{(t)} \log \left(p_{ik}^{(t)} \right) \right\}_{t=1}^T, \quad (1)$$

where $p_{ik}^{(t)}$ denotes the posterior localisation probability of protein i to component k at iteration t . We then summarise this as a Monte-Carlo averaged Shannon entropy. The greater the Shannon entropy the more uncertainty associated with the assignment of this protein. The lower the Shannon entropy the lower the uncertainty associated with the assignment of this protein. In figure 11 panel (a), we visualise the Shannon entropy of each protein in a PCA plot, by scaling the pointers in accordance to this metric. We also note that while localisation probability (of a protein to its most probable location) and the Shannon entropy are correlated, figure 11 panel (c), it is not perfect. Thus it is important to use both the localisation probabilities and the uncertainty in these assignments to make conclusions.

Figure 11 demonstrates that the regions of highest uncertainty are those in regions where organelles assignments overlap. The conclusions from this plot are manifold. Firstly, many proteins are assigned unambiguously to sub-cellular localisations; that is, not only are some proteins assigned to organelles with high probability but also with low uncertainty. Secondly, there are well defined regions with high uncertainty, for example proteins in the secretory pathway or proteins on the boundary between cytosol and proteasome. Finally, some organelles, such as the mitochondria, are extremely well resolved. This observed uncertainty in the secretory pathway and cytosol could be attributed to the dynamic nature of these parts of the cell with numerous examples of proteins that traffic in and out of these sub-cellular compartments as part of their biological role. Moreover, the organelles of the secretory pathway share similar and overlapping physical properties making their separation from one another using biochemical fractionation more challenging. Furthermore, there is a region located in the centre of the plot where proteins simultaneously have low probability of belonging to any organelle and high uncertainty in their localisation probability. This suggests that these proteins are poorly described by any single location. These proteins could belong to multiple locations or belong to undescribed sub-cellular compartments. The information displayed in these plots and the conclusion therein would be extremely challenging to obtain without the use of Bayesian methodology.




Figure 11: PCA plots of the mouse pluripotent embryonic stem cell data, where each point represents a protein and is coloured to its (probabilistically-)assigned organelle. (a) In this plot, the pointer is scaled to the Shannon entropy of this protein, with larger pointers indicating greater uncertainty. (b) In this plot, the pointer is scaled to the probability of that protein belonging to its assigned organelle. (c) We plot the localisation probabilities against the Shannon entropy with each protein.

3 Discussion

We have demonstrated that a Bayesian framework, based on Gaussian mixture models, for spatial proteomics can provide whole sub-cellular proteome uncertainty quantification on the assignment of proteins to organelles and such information is invaluable. Performing MAP inference using our generative model provides fast and straightforward approach, which is vital for quality control and early data exploration. Full posterior inference using MCMC provides not only point estimates of the posterior probability that a protein belongs to a particular sub-cellular niche, but uncertainty in this assignment. Then, this uncertainty can be summarised in several ways, including, but not limited to, equi-tailed credible intervals of the Monte-Carlo samples of posterior localisation probabilities. Posterior distributions for individual proteins can then be rigorously interrogated to shed light on their biological mechanisms; such as, transport, signalling and interactions.

As well as the local uncertainty seen by exploring individual proteins, we further explored using a Monte-Carlo averaged Shannon entropy to visualise global uncertainty. Regions of high uncertainty, as measured using this Shannon entropy, reflect highly dynamics regions of the sub-cellular environment. Hence, biologists can now explore uncertainty at different levels and then are able to make quantifiable conclusions and insights about their data. Furthermore, our Bayesian model is interpretable and our inferences are fully conditional on our data, allowing them to be easily modified with changing experimental design.

In addition, we produced competitive classifier performance to the state-of-the-art classifiers. We considered two traditional machine-learning methods: the SVM and KNN classifiers; as well as two classifiers based on our model: a MAP classifier and classification based on MCMC. We compared all methods on 19 different spatial proteomics datasets, across four different organisms. When considering the macro-F1 score as a performance metric, no single classifier outperformed another across all datasets. However, using MCMC based inference our method significantly outperforms the SVM and KNN classifiers with respect to the quadratic loss in 16 out of 19 datasets. This allows us to have greater confidence in our conclusions when they are drawn from our Bayesian inferences. Furthermore, using MCMC provides a wealth of additional information, and so becomes the method of choice for analysing spatial proteomics data.

Analysis of a *hyper*LOPIT experiment applied to mouse pluripotent embryonic stem cells demonstrated that the additional layer of information that our model provides is biologically relevant and provides further avenues for additional exploration. Moreover, applying our method to a biologically significant dataset now provides the scientific community with localisation information on up to 4000 proteins for the mouse pluripotent stem cell proteome. Figure 12 demonstrates that from an initial input of roughly 1000 marker proteins with *a priori* known location and 4000 unknown proteins with unknown location, SVM and TAGM-MCMC can provide rigorous localisation information on roughly 2000 proteins. However, our methodology, by also considering uncertainty, allows us to obtain information on another 1000 proteins. Thus, we have augmented this dataset by providing uncertainty quantification on the localisation of proteins to their sub-cellular niches, which had been previously unavailable. We note that our method is general enough to be applied to many MS-based spatial proteomics protocols including: LOPIT, *hyper*LOPIT, protein correlation profiling (PCP) (Foster *et al.*, 2006), differential centrifugation approaches and spatio-temporal pro-

teomics methods. In our flexible software implementation, all hyperparameters for the priors
can be changed if users have precise priors they wish to specify.




Figure 12: The barplot demonstrates the effect of applying different methodologies on protein assignment when applied the mouse pluripotent embryonic stem cell data. Roughly 2000 proteins are classified using either SVM and TAGM-MCMC; however, TAGM-MCMC can draw additional conclusions about an extra 1000 proteins by quantifying uncertainty.

We have also provided a new set of visualisation methods to accompany our model, which
allow us to easily interrogate our data. High quality visualisation tools are essential for
rigorous quality control and sound biological conclusions. Our methods have been developed
in the R statistical programming language and we continue to contribute to the Bioconductor
project (Gentleman *et al.*, 2004; Huber *et al.*, 2015) with inclusion of our methods within
the pRoloc package ($\geq 1.21.1$) (Gatto *et al.*, 2014b). The underlying source code used to
generate this document is available at <https://github.com/lgatto/2018-TAGM-paper>.

Currently, our model does not integrate localisation information from different data
sources, nor does it explicitly model proteins with multiple localisation. However, one (of
many) biological explanations for the uncertainty that we model in the allocation probab-
ilities is provided by multiple localisation. Thus a protein for which it is uncertain to which
two sub-cellular niches it is resident within it is perhaps resident of both niches. In further
work, we plan to explicitly model such cases to deconvolute different sources of uncertainty.
In addition, extensions to semi-supervised non-parametric methods are under consideration
to detect novel sub-cellular niches. These are the subjects of further work.

4 Model and methods

We describe in this section the probabilistic model that uses the labelled data to associate un-annotated proteins to specific organelles or sub-cellular compartments.

4.1 Mixture models for spatial proteomic data

We observe N protein profiles each of length L , corresponding to the number of quantified fractions along the gradient density, including combining replicates. For $i = 1, \dots, N$, we denote the profile of the i -th protein by $\mathbf{x}_i = [x_{1i}, \dots, x_{Li}]$. We suppose that there are K known sub-cellular compartments to which each protein could localise (e.g. cytoplasm, endoplasmic reticulum, mitochondria, ...). Henceforth, we refer to these K sub-cellular compartments as *components*, and introduce component labels z_i , so that $z_i = k$ if the i -th protein localises to the k -th component. We denote by X_L the set of proteins whose component labels are known, and by X_U the set of unlabelled proteins. If protein i is in X_U , we desire the probability that $z_i = k$ for each $k = 1, \dots, K$. That is, for each unlabelled protein, we want the probability of belonging to each component (given a model and the observed data).

We initially model the distribution of profiles associated with proteins that localise to the k -th component as multivariate normal with mean vector $\boldsymbol{\mu}_k$ and covariance matrix Σ_k , so that:

$$\mathbf{x}_i | z_i = k \sim \mathcal{N}(\boldsymbol{\mu}_k, \Sigma_k). \quad (2)$$

For any i , we define the prior probability of the i -th protein localising to the k -th component to be $p(z_i = k) = \pi_k$. Letting $\boldsymbol{\theta} = \{\boldsymbol{\mu}_k, \Sigma_k\}_{k=1}^K$ denote the set of all component mean and covariance parameters, and $\boldsymbol{\pi} = \{\pi_k\}_{k=1}^K$ denote the set of all mixture weights, it follows (from the law of total probability) that:

$$p(\mathbf{x}_i | \boldsymbol{\theta}, \boldsymbol{\pi}) = \sum_{k=1}^K \pi_k f(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k), \quad (3)$$

where $f(\mathbf{x} | \boldsymbol{\mu}, \Sigma)$ denotes the density of the multivariate normal with mean vector $\boldsymbol{\mu}$ and covariance matrix Σ evaluated at \mathbf{x} .

Equation (3) defines a generative probabilistic model known as a *mixture model*. Such models are useful for describing populations that are composed of a number of distinct homogeneous subpopulations. In our case, we model the full complement of measured proteins as being composed of K subpopulations, each corresponding to a different organelle or sub-cellular compartment. The literature of mixture model applications to biology is rich and some recent example include applications to retroviral integration sites (Kirk *et al.*, 2016), genome-wide associations studies (Liley *et al.*, 2017), single-cell transcriptomics (Lönnerberg *et al.*, 2017) and affinity purification MS proteomics (Choi *et al.*, 2010).

Though some proteins are well described as belonging to a single component, many proteins multi-localise or might belong to uncharacterised organelles. In order to allow the

513 model to better account for these "outliers" that cannot be straightforwardly allocated to
 514 any single known component, we extend it by introducing an additional "outlier component".
 515 To do this, we augment our model by introducing a further indicator latent variable ϕ . Each
 516 protein \mathbf{x}_i is now described by an additional variable ϕ_i , with $\phi_i = 1$ indicating that protein
 517 \mathbf{x}_i belongs to a organelle derived component and $\phi_i = 0$ indicating that protein \mathbf{x}_i is not well
 518 described by these known components. This outlier component is modelled as a multivariate
 519 T distribution with degrees of freedom κ , mean vector \mathbf{M} , and scale matrix V . Thus equation
 520 (2) becomes

$$\mathbf{x}_i | z_i = k, \phi_i \sim \mathcal{N}(\boldsymbol{\mu}_k, \Sigma_k)^{\phi_i} \mathcal{T}(\kappa, \mathbf{M}, V)^{1-\phi_i}. \quad (4)$$

521 Further let $g(\mathbf{x}|\kappa, \mathbf{M}, \mathbf{V})$ denote the density of the multivariate T-distribution so that
 522 Equation (3) becomes:

$$p(\mathbf{x}_i | \boldsymbol{\theta}, \boldsymbol{\pi}, \phi_i, \kappa, \mathbf{M}, V) = \sum_{k=1}^K \pi_k \left(f(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k)^{\phi_i} g(\mathbf{x}_i | \kappa, \mathbf{M}, V)^{1-\phi_i} \right). \quad (5)$$

523 For any i , we define the prior probability of the i -th protein belonging to the outlier
 524 component as $p(\phi_i = 0) = \epsilon$.

525 We can then rewrite equation (5) in the following way:

$$p(\mathbf{x}_i | \boldsymbol{\theta}, \boldsymbol{\pi}, \kappa, \epsilon, \mathbf{M}, V) = \sum_{k=1}^K \pi_k \left((1 - \epsilon) f(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i | \kappa, \mathbf{M}, V) \right), \quad (6)$$

526 Throughout we take $\kappa = 4$, \mathbf{M} as the global mean, and V as half the global variance of
 527 the data, including labelled and unlabelled proteins. The reason for formulating the model
 528 as in equation (5) is because it leads to a flexible modelling framework. Furthermore, ϕ has
 529 an elegant model selection interpretation, since it decides whether \mathbf{x}_i is better modelled by
 530 the known components or the outlier component. It is important to note that f and g could
 531 be replaced by many combinations of distributions and thus could be valuable in modelling
 532 other datasets. The choice of parameters for the multivariate T-distribution was decided
 533 so that it mimicked a multivariate normal component with the same mean and variance
 534 but with heavier tails to better capture dispersed proteins, which we refer to as outlier
 535 proteins throughout the text. The variance of the multivariate T-distribution is designed to
 536 be large such that is relatively flat when compared with multivariate Gaussian distributions
 537 which describe annotated components. Similar approaches for modelling outliers have been
 538 explored in the literature and often the outlier term is considered constant or as a Poisson
 539 process, independent of the observation (Banfield and Raftery, 1993; Cooke *et al.*, 2011;
 540 Coretto and Hennig, 2016; Hennig, 2004).

541 4.2 Model fitting

542 We adopt a Bayesian approach toward inferring the unknown parameters, $\boldsymbol{\theta} = \{\boldsymbol{\mu}_k, \Sigma_k\}_{k=1}^K$,
 543 $\boldsymbol{\pi} = \{\pi_k\}_{k=1}^K$, and ϵ of the mixture model presented in Equation (5). For $\boldsymbol{\pi}$, we take a

544 conjugate symmetric Dirichlet prior with parameter β , so that $\pi_1, \dots, \pi_K \sim \text{Dirichlet}(\beta)$;
 545 and for the component-specific parameters μ_k and Σ_k we take conjugate normal-inverse-
 546 Wishart (NIW) priors with parameters $\{\mu_0, \lambda_0, \nu_0, S_0\}$, so that:

$$\mu_k, \Sigma_k \sim \mathcal{N}\left(\mu_k | \mu_0, \frac{\Sigma_k}{\lambda_0}\right) IW(\Sigma_k | \nu_0, S_0). \quad (7)$$

547 We also place a conjugate Beta prior on ϵ with parameters u and v , so that $\epsilon \sim \mathcal{B}(u, v)$.
 548 Allowing ϵ to be random allows us to infer the number of proteins that are better described
 549 by an outlier component rather than any known component.

550 The full model, which we henceforth refer to as a T-augmented Gaussian Mixture model
 551 (TAGM), can then be summarised by the plate diagram shown in Figure 13.




Figure 13: Plate diagram for TAGM model. This diagram specifies the conditional independencies and parameters in our model.

552 To perform inference for the parameters, we make use of both the labelled and unlabelled
 553 data. For the labelled data X_L , since z_i and ϕ_i are known for these proteins, we can update
 554 the parameters with their data analytically by exploiting conjugacy of the priors (see, for
 555 example, [Gelman *et al.*, 1995](#)). For the unlabelled data we do not have such information and
 556 so in the next sections we explain how to make inferences of the latent variables.

557 4.3 Prediction of localisation of unlabelled proteins

558 Having obtained the posterior distribution of the model parameters analytically using, at
 559 first, the labelled data only, we wish to predict the component to which each of the unlabelled
 560 proteins belongs. The probability that a protein belongs to any of the K known components,
 561 that is $z_i = k$ and $\phi_i = 1$, is given by (see appendix 5.1 for derivations):

$$p(\phi_i = 1, z_i = k | \mathbf{x}_i, \boldsymbol{\theta}, \boldsymbol{\pi}, \epsilon, \kappa, \mathbf{M}, V) = \frac{\pi_k (1 - \epsilon) f(\mathbf{x}_i | \mu_k, \Sigma_k)}{\sum_{k=1}^K \pi_k ((1 - \epsilon) f(\mathbf{x}_i | \mu_k, \Sigma_k) + \epsilon g(\mathbf{x}_i | \kappa, \mathbf{M}, V))}, \quad (8)$$

whilst on the other hand,

$$p(\phi_i = 0, z_i = k | \mathbf{x}_i, \boldsymbol{\theta}, \boldsymbol{\pi}, \kappa, \epsilon, \mathbf{M}, V) = \frac{\pi_k \epsilon g(\mathbf{x}_i | \kappa, \mathbf{M}, V)}{\sum_{k=1}^K \pi_k ((1 - \epsilon) f(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i | \kappa, \mathbf{M}, V))}. \quad (9)$$

Processing of the unlabelled data can be done by inferring *maximum a posteriori* (MAP) estimates for the parameters. However, this approach fails to account for the uncertainty in the parameters, thus we additionally explore inferring the distribution over these parameters.

4.3.1 Maximum a posteriori prediction

We use the Expectation-Maximisation (EM) algorithm (Dempster *et al.*, 1977) to find *maximum a posteriori* (MAP) estimates for the parameters (see, for example, Murphy, 2012). To specify the parameters of the prior distributions, we use a simple set of heuristics provided by Fraley and Raftery (2007). By defining the following quantities

$$\begin{aligned} a_{ik} &= p(z_i = k, \phi_i = 1 | \mathbf{x}_i), b_{ik} = p(z_i = k, \phi_i = 0 | \mathbf{x}_i) \\ w_{ik} &= p(z_i = k | x_i) = a_{ik} + b_{ik} \\ a_k &= \sum_{i=1}^n a_{ik}, a = \sum_{k=1}^K a_k \\ b_k &= \sum_{i=1}^n b_{ik}, b = \sum_{k=1}^K b_k \\ r_k &= \sum_{i=1}^n w_{ik}, \end{aligned} \quad (10)$$

we can compute

$$\begin{aligned} \lambda_k &= \lambda_0 + a_k, \\ \nu_k &= \nu_0 + a_k, \\ m_k &= \frac{a_k \bar{\mathbf{x}}_k + \lambda_0 \mu_0}{\lambda_k}, \\ S_k^{-1} &= S_0^{-1} + \frac{\lambda_0 a_k}{\lambda_k} (\bar{\mathbf{x}}_k - \mu_0)^T (\bar{\mathbf{x}}_k - \mu_0) + \sum_{i=1}^n a_{ik} (x_i - \bar{\mathbf{x}}_k)^T (x_i - \bar{\mathbf{x}}_k). \end{aligned} \quad (11)$$

Then the parameters of the posterior mode are:

$$\begin{aligned} \hat{\mu}_k &= m_k \\ \hat{\Sigma}_k &= \frac{1}{\nu_k + D + 2} S_k^{-1}. \end{aligned} \quad (12)$$

We note if \mathbf{x}_i is a labelled protein then $a_{ik} = 1$ and these parameters can be updated without difficulty. The above equation constitutes a backbone of the E-step of the EM algorithm, with the entire algorithm specified by the following summary:

E-Step: Given the current parameters compute the values given by equations (10), with formulae provided in equations (8) and (9).

M-Step: Compute

$$\epsilon = \frac{u + b - 1}{(a + b) + (u + v) - 2},$$

and

$$\pi_k = \frac{r_k + \beta_k - 1}{N + \sum \beta_k - K},$$

as well as

$$\bar{\mathbf{x}}_k = \frac{1}{a_k} \left(\sum_{i=i}^n a_{ik} \mathbf{x}_i \right).$$

Finally, compute the MAP estimates given by equations (12). These estimates are then used in the following iteration of the E-step.

Denoting by Q the expected value of the log-posterior and letting t denote the current iteration of the EM algorithm, we iterate until $|Q(\boldsymbol{\theta}|\boldsymbol{\theta}_t) - Q(\boldsymbol{\theta}|\boldsymbol{\theta}_{t-1})| < \delta$ for some pre-specified $\delta > 0$. Once we have found MAP estimates for the parameters $\boldsymbol{\theta}_{MAP}$, $\boldsymbol{\pi}_{MAP}$ and ϵ_{MAP} we proceed to perform prediction. We plug the MAP parameter estimates into Equation (8) in order to obtain the posterior probability of protein i localising to component k , $p(z_i = k, \phi = 1|\mathbf{x}_i, \boldsymbol{\theta}_{MAP}, \boldsymbol{\pi}_{MAP}, \epsilon_{MAP}, \kappa, \mathbf{M}, V)$. To make a final assignment, we may allocate each protein according to the component that has maximal probability. A full technical derivation of the EM algorithm can be found in the appendix (appendix 5.1).

4.3.2 Uncertainty in the posterior localisation probabilities

The MAP approach described above provides us with a probabilistic assignment, $p(z_i = k, \phi = 1|\mathbf{x}_i, \boldsymbol{\theta}_{MAP}, \boldsymbol{\pi}_{MAP}, \epsilon_{MAP}, \kappa, \mathbf{M}, V)$, of each unlabelled protein to each component. However, it fails to account for the uncertainty in the parameters $\boldsymbol{\theta}$, $\boldsymbol{\pi}$ and ϵ . To address this, we can sample parameters from the posterior distribution.

Let $\{\boldsymbol{\theta}^{(t)}, \boldsymbol{\pi}^{(t)}, \epsilon^{(t)}\}_{t=1}^T$ be a set of T sampled values for the parameters $\boldsymbol{\theta}$, $\boldsymbol{\pi}$, ϵ , drawn from the posterior.

The assignment probabilities can then be summarised by the Monte-Carlo average:

$$p(z_i = k, \phi = 1|\mathbf{x}_i, \epsilon, \mathbf{M}, V) \approx T^{-1} \sum_{t=1}^T p(z_i = k, \phi = 1|\mathbf{x}_i, \boldsymbol{\theta}^{(t)}, \boldsymbol{\pi}^{(t)}, \epsilon^{(t)}, \kappa, \mathbf{M}, V).$$

Other summaries of the assignment probabilities can be determined in the usual ways to obtain, for example, interval-estimates. We summarise interval-estimates using the 95% equi-tailed interval, which is defined by the 0.025 and 0.975 quantiles of the distribution of assignment probabilities, $\{p(z_i = k, \phi = 1|\mathbf{x}_i, \boldsymbol{\theta}^{(t)}, \boldsymbol{\pi}^{(t)}, \epsilon^{(t)}, \mathbf{M}, V)\}_{t=1}^T$.

Sampling parameter values in our model requires us to compute the required conditional probabilities and then a straightforward Gibbs sampler can be used to sample in turn from these conditionals. In addition, we can bypass sampling the parameters by exploiting the conjugacy of our priors. By marginalising parameters in our model we can obtain an efficient

collapsed Gibbs sampler and therefore only sample the component allocation probabilities and the outlier allocation probabilities. The derivations and required conditionals can be found in the appendix (appendix 5.2).

4.4 Classifier assessment

We compared the classification performance of the two above learning schemes to the K-nearest neighbours (KNN) and the weighted support vector machine (SVM) classifiers.

The following schema was used to assess the classifier performance of all methods. We split the marker sets for each experiment into a class-stratified training (80%) and test (20%) partitions, with the separation formed at random. The true classes of the test profiles are withheld from the classifier, whilst the algorithm is trained. The algorithm is then assessed on its ability to predict the classes of the proteins in the test partition for generalisation accuracy. How each classifier is trained is specific to that classifier. The KNN and SVM have hyperparameters optimised using 5-fold cross-validation. This 80/20 data stratification is performed 100 times in order to produce 100 sets of macro-F1 (He and Garcia, 2009) scores and class specific F1 scores (Breckels *et al.*, 2016b). The F1 score is the harmonic mean of the precision and recall, more precisely:

$$\text{precision} = \frac{tp}{tp + fp}, \text{recall} = \frac{tp}{tp + fn}.$$

tp denotes the number of true positives; fp the number of false positives and fn the number of false negatives. Thus

$$F1 = 2 \times \frac{\text{precision} \times \text{recall}}{\text{precision} + \text{recall}}.$$

High Macro F1 scores indicates that marker proteins in the test dataset are consistently correctly assigned by the classifier. We note that accuracy alone is an inadequate measure of performance, since it fails to quantify false positives.

However, a Bayesian Generative classifier produces probabilistic assignment of observations to classes. Thus while the classifier may make an incorrect assignment it may do so with low probability. The F1 score is unforgiving in this situation and will not use this information. To measure this uncertainty, we introduce the quadratic loss which allows us to compare probabilistic assignments (Gneiting and Raftery, 2007). For the SVM, a logistic distribution is fitted using maximum likelihood estimation to the decision values of all binary classifiers. Then, the membership probabilities for the multi-class classification is calculated using quadratic optimisation. The logistic regression model assumes errors which are distributed according to a centred Laplace distribution for the predictions, where maximum likelihood estimation is used to estimate the scale parameter (Meyer *et al.*, 2017). For the KNN classifier, we interpret the proportion of neighbours belonging to each class as a non-parametric posterior probability. To avoid non-zero probabilities for classes we perform Laplace smoothing; that is, the posterior allocation probability is given by

$$p(z_i = k|x_i) = \frac{N_{ik} + \alpha d_k C}{K + \alpha C}, \quad (13)$$

where N_{ik} is the number of neighbours belonging to class k in the neighbourhood of x_i , C is the number of classes, K is the number of nearest neighbours (optimised through 5-fold cross validation) and d_k is the incidence rate of each class in the training set. Finally, $\alpha > 0$ is the pseudo-count smoothing parameter. Motivated by a Bayesian interpretation of placing a Jeffrey’s type Dirichlet prior over multinomial counts, we choose $\alpha = 0.5$ (Hazimeh and Zhai, 2015; Valcarce *et al.*, 2016; Manning *et al.*, 2008). The quadratic loss is given by the following formula:

$$Q_2 = \sum_{i=1}^N \|q_i - p_i\|_2^2, \quad (14)$$

where $\|\cdot\|_2$ is the l_2 norm and q_i is the true classification vector and p_i is a vector of predicted assignments to each class. It is useful to note that the corresponding risk function is the mean square error (MSE), which is the expected value of the quadratic loss.

Acknowledgments

The authors would also like to thank Dr Sean B. Holden, University of Cambridge, for helpful discussions.

5 Appendices

5.1 Appendix 1: Derivation of EM algorithm for TAGM model

This appendix give a formal derivation of the EM algorithm used for our model. Computations are standard but useful and similar technical summaries can be found (for example see [Fraley and Raftery \(2005\)](#); [Murphy \(2007\)](#)) We let $H = \{\boldsymbol{\mu}_0, \lambda_0, \nu_0, S_0\}$ denote the parameters of the normal-inverse-Wishart prior. More precisely:

$$\boldsymbol{\mu}_k, \Sigma_k \sim \mathcal{N}\left(\boldsymbol{\mu}_k | \boldsymbol{\mu}_0, \frac{\Sigma_k}{\lambda_0}\right) IW(\Sigma_k | \nu_0, S_0). \quad (15)$$

Furthermore, let $\boldsymbol{\theta}_k = \{\boldsymbol{\mu}_k, \Sigma_k\}$, and let $\Theta = \{\kappa, \mathbf{M}, V\}$ be the parameters of the global \mathcal{T} distribution. We specify the following hierarchical Bayesian model.

$$\begin{aligned} \pi | \beta &\sim Dir(\beta), \\ \theta_k | H &\sim \mathcal{NIW}(H), \\ z_i | \pi &\sim cat(\pi), \\ \epsilon | u, v &\sim \mathcal{B}(u, v) \\ \phi_i | \epsilon &\sim Ber(1 - \epsilon) \end{aligned} \quad (16)$$

$$\mathbf{x}_i | z_i = k, \theta, \Phi, \Theta \sim \mathcal{N}(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k)^{\mathbb{1}(\phi_i=1)} \mathcal{T}(\mathbf{x}_i | \kappa, \mathbf{M}, V)^{\mathbb{1}(\phi_i=0)}$$

Since $p(\phi_i = 1) = 1 - \epsilon$, we can rewrite the last line of the model (16) as the following:

$$p(\mathbf{x}_i | z_i = k, \theta, \Phi, \Theta) = (1 - \epsilon) \mathcal{N}(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k) + \epsilon \mathcal{T}(\mathbf{x}_i | \kappa, \mathbf{M}, V).$$

The total joint probability is

$$\begin{aligned} p(\theta, \Theta, X, Z, \Phi) &= p(X, Z, \Phi | \theta, \pi, \epsilon) p(\epsilon | u, v) p(\theta | H) p(\pi | \beta) \\ &= \prod_{i=1}^n \prod_{k=1}^K \left(\pi_k ((1 - \epsilon) \mathcal{N}(x_i | \boldsymbol{\mu}_k, \Sigma_k))^{\mathbb{1}(\phi_i=1)} (\epsilon \mathcal{T}(x_i | \kappa, \mathbf{M}, V))^{\mathbb{1}(\phi_i=0)} \right)^{\mathbb{1}(z_i=k)} \\ &\quad \cdot \left(\prod_{k=1}^K \mathcal{NIW}(H) \right) \cdot Dir(\beta) \cdot \mathcal{B}(u, v). \end{aligned} \quad (17)$$

Before we formally derive an EM algorithm for this model, we derive a few useful quantities. Let $f(\mathbf{x} | \boldsymbol{\mu}, \Sigma)$ denote the density of the multivariate normal with mean vector $\boldsymbol{\mu}$ and covariance matrix Σ evaluated at \mathbf{x} and further let $g(\mathbf{x} | \kappa, \mathbf{M}, V)$ denote the density of the multivariate T-distribution. We compute that

$$\begin{aligned}
p(\phi_i = 1|z_i = k, \mathbf{x}_i) &= \frac{p(\phi_i = 1, \mathbf{x}_i|z_i = k)}{p(\mathbf{x}_i|z_i = k)} \\
&= \frac{p(\mathbf{x}_i|z_i = k, \phi_i = 1)P(\phi_i = 1|z_i = k)}{p(\mathbf{x}_i|z_i = k)} \\
&= \frac{(1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k)}{(1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V)}.
\end{aligned} \tag{18}$$

668 Likewise we see that,

$$p(\phi_i = 0|z_i = k, \mathbf{x}_i) = \frac{\epsilon f(\mathbf{x}_i|M, V)}{(1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V)}. \tag{19}$$

669 Thus

$$\begin{aligned}
&p(\phi_i = 1, z_i = k|\mathbf{x}_i) \\
&= p(\phi_i = 1|z_i = k, \mathbf{x}_i)p(z_i = k|\mathbf{x}_i) \\
&= p(\phi_i = 1|z_i = k, \mathbf{x}_i) \frac{p(\mathbf{x}_i|z_i = k)p(z_i = k)}{p(\mathbf{x}_i)} \\
&= p(\phi_i = 1|z_i = k, \mathbf{x}_i) \frac{(p(\mathbf{x}_i|z_i = k, \phi_i = 0)p(\phi_i = 0) + p(\mathbf{x}_i|z_i = k, \phi_i = 1)p(\phi_i = 1))p(z_i = k)}{p(\mathbf{x}_i)}
\end{aligned} \tag{20}$$

670 and then substituting values leads to

$$\begin{aligned}
&\frac{(1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k)}{(1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V)} \frac{\pi_k((1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V))}{\sum_{k=1}^K \pi_k((1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V))} = \\
&\frac{\pi_k(1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k)}{\sum_{k=1}^K \pi_k((1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V))}.
\end{aligned} \tag{21}$$

671 We also see that

$$p(\phi_i = 0, z_i = k|\mathbf{x}_i) = \frac{\pi_k \epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V)}{\sum_{k=1}^K \pi_k((1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k) + \epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V))}. \tag{22}$$

672 We can now formally derive the EM algorithm for this model. First, we compute the
673 expected value of the log-posterior function with respect to the conditional distribution of
674 the latent variable given the observations (under the current estimate of the parameters).
675 For notational convenience we suppress the dependence on the parameters.

$$\begin{aligned}
Q(\boldsymbol{\theta}|\hat{\boldsymbol{\theta}}) &= E_{Z, \Phi|X, \hat{\boldsymbol{\theta}}}[\log p(\boldsymbol{\theta}; X, Z, \Phi)] \\
&= \sum_{i=1}^n E_{Z, \Phi|X, \hat{\boldsymbol{\theta}}}[\log p(\boldsymbol{\theta}; \mathbf{x}_i, z_i, \phi_i)] \\
&= \sum_{i=1}^n \sum_{k=1}^K \sum_{r=0}^1 p(z_i = k, \phi_i = r|\mathbf{x}_i) \log(L(\boldsymbol{\theta}_k|\mathbf{x}_i, z_i = k, \phi_i)) + \log(p(\pi) + \sum_{k=1}^K \log(p(\boldsymbol{\theta}_k))) \\
&= \sum_{i=1}^n \sum_{k=1}^K \sum_{r=0}^1 p(z_i = k, \phi_i = r|\mathbf{x}_i) \log(p(\mathbf{x}_i, z_i = k, \phi_i|\boldsymbol{\theta}_k)) + \log(p(\pi) + \sum_{k=1}^K \log(p(\boldsymbol{\theta}_k))) \\
&= Q'(\boldsymbol{\theta}|\hat{\boldsymbol{\theta}}) + D(\boldsymbol{\pi}, \boldsymbol{\theta})
\end{aligned} \tag{23}$$

676 We note that the equation splits up into a likelihood term Q' plus the log prior D . The
677 coefficient of the first term in the equation above has already been derived and the other
678 term is given by:

$$\begin{aligned}
p(\mathbf{x}_i, z_i = k, \phi_i|\boldsymbol{\theta}_k) &= p(\mathbf{x}_i, \phi_i|\boldsymbol{\theta}_k, z_i = k)p(z_i = k|\boldsymbol{\theta}_k) \\
&= \pi_k p(\mathbf{x}_i, \phi_i|\boldsymbol{\theta}_k, z_i = k) \\
&= \pi_k (p(\mathbf{x}_i|\boldsymbol{\theta}_k, z_i = k, \phi_i)p(\phi_i|\boldsymbol{\theta}_k, z_i = k)) \\
&= \pi_k (((1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k))^{\phi_i} (\epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V))^{1-\phi_i}),
\end{aligned} \tag{24}$$

679 where we used that ϕ_i was a binary random variable. Thus we see that

$$\begin{aligned}
Q'(\boldsymbol{\theta}|\hat{\boldsymbol{\theta}}) &= \sum_{i=1}^n \sum_{k=1}^K \sum_{\Phi} p(z_i = k, \phi_i|\mathbf{x}_i) \log(p(\mathbf{x}_i, z_i = k, \phi_i|\boldsymbol{\theta}_k)) \\
&= \sum_{i=1}^n \sum_{k=1}^K \sum_{\Phi} p(z_i = k, \phi_i|\mathbf{x}_i) \log(\pi_k ((1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k))^{\phi_i} (\epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V))^{1-\phi_i}) \\
&= \sum_{i=1}^n \sum_{k=1}^K \sum_{\Phi} p(z_i = k, \phi_i|\mathbf{x}_i) (\log(\pi_k) + \phi_i \log((1 - \epsilon)f(\mathbf{x}_i|\boldsymbol{\mu}_k, \Sigma_k)) + (1 - \phi_i) \log(\epsilon g(\mathbf{x}_i|\kappa, \mathbf{M}, V))) \\
&= (A) + (B) + (C) + (D)
\end{aligned} \tag{25}$$

680 where

$$\begin{aligned}
(A) &= \sum_{i=1}^n \sum_{k=1}^K p(z_i = k | \mathbf{x}_i) \log(\pi_k) \\
(B) &= \sum_{i=1}^n \sum_{k=1}^K \sum_{\Phi} p(z_i = k, \phi_i | \mathbf{x}_i) (\phi_i \log(1 - \epsilon) + (1 - \phi_i) \log(\epsilon)) \\
(C) &= \sum_{i=1}^n \sum_{k=1}^K \sum_{\Phi} p(z_i = k, \phi_i | \mathbf{x}_i) \phi_i \log(f(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k)) \\
(D) &= \sum_{i=1}^n \sum_{k=1}^K \sum_{\Phi} p(z_i = k, \phi_i | \mathbf{x}_i) (1 - \phi_i) \log(g(\mathbf{x}_i | \kappa, \mathbf{M}, V)).
\end{aligned} \tag{26}$$

681 Then again using that ϕ_i is binary we can make the following simplifications.

$$\begin{aligned}
(B) &= \sum_{i=1}^n \sum_{k=1}^K p(z_i = k, \phi_i = 1 | \mathbf{x}_i) \log(1 - \epsilon) + p(z_i = k, \phi_i = 0 | \mathbf{x}_i) \log(\epsilon) \\
(C) &= \sum_{i=1}^n \sum_{k=1}^K p(z_i = k, \phi_i = 1 | \mathbf{x}_i) \log(f(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k)) \\
(D) &= \sum_{i=1}^n \sum_{k=1}^K p(z_i = k, \phi_i = 0 | \mathbf{x}_i) \log(g(\mathbf{x}_i | \kappa, \mathbf{M}, V)).
\end{aligned} \tag{27}$$

682 Terms can now be maximised by considering terms independently because of linearity.
683 Note that the equations 8 and 9 are computed with respect to the current estimated values
684 of the parameters. For convenience set the following notation

$$\begin{aligned}
a_{ik} &= p(z_i = k, \phi_i = 1 | \mathbf{x}_i) \\
b_{ik} &= p(z_i = k, \phi_i = 0 | \mathbf{x}_i) \\
w_{ik} &= p(z_i = k | \mathbf{x}_i) = a_{ik} + b_{ik} \\
a_k &= \sum_{i=1}^n a_{ik}, a = \sum_{k=1}^K a_k \\
b_k &= \sum_{i=1}^n b_{ik}, b = \sum_{k=1}^K b_k \\
r_k &= \sum_{i=1}^n w_{ik}
\end{aligned} \tag{28}$$

685 The maximisation step requires finding $\operatorname{argmax}_{\boldsymbol{\theta}} Q(\boldsymbol{\theta} | \hat{\boldsymbol{\theta}})$, this can be found for parameter
686 separately for each linear term. To find $\hat{\epsilon}$, we need only consider computing the maximisation
687 step from equation (B). First set $\epsilon_1 = 1 - \epsilon$ and $\epsilon_2 = \epsilon$ and add the log prior term to equation
688 (B). Thus, the required Lagrangian is

$$\mathcal{L}_\epsilon = a \log(\epsilon_1) + b \log(\epsilon_2) + (u-1) \log(\epsilon_2) + (v-1) \log((\epsilon_1) + \lambda(\epsilon_1 + \epsilon_2 - 1) + \text{constant}. \quad (29)$$

689 Solving this system leads to

$$\epsilon = \frac{u+b-1}{(a+b) + (u+v) - 2}. \quad (30)$$

690 To find the MAP estimate for $\boldsymbol{\pi}$, we examine equation (A) and add the log prior. Fur-
691 thermore we must maximise $\boldsymbol{\pi}$ under the constraint that $\sum_{k=1}^K \pi_k = 1$. The Lagrangian for
692 this constrained optimisation problem is the following,

$$\mathcal{L} = \sum_{i=1}^n \sum_{k=1}^K w_{ik} \log(\pi_k) - \log(B(\beta)) + \sum_{k=1}^K (\beta_k - 1) \log(\pi_k) + \lambda \left(\sum_{k=1}^K \pi_k - 1 \right). \quad (31)$$

693 The fixed point of this Lagrangian solves the required constrained optimisation problem
694 and $B(\beta)$ denotes the Beta function with parameter β .

$$\begin{aligned} \frac{\partial \mathcal{L}}{\partial \pi_k} &= \frac{r_k}{\pi_k} + \frac{\beta_k - 1}{\pi_k} + \lambda = 0 \\ \frac{\partial \mathcal{L}}{\partial \lambda} &= \sum_{k=1}^K \pi_k - 1 = 0 \end{aligned} \quad (32)$$

695 Solving this pair of equations yields

$$\pi_k = \frac{r_k + \beta_k - 1}{N + \sum \beta_k - K}. \quad (33)$$

696 To find the posterior mode of the remaining parameters requires some work. First we
697 recall that the normal inverse-Wishart prior is proportional to:

$$\prod_{k=1}^K |\Sigma_k|^{\frac{\nu_0 + D + 2}{2}} \exp \left(-\frac{1}{2} \text{tr}(\Sigma_k^{-1} S_0^{-1}) \right) \exp \left(-\frac{\lambda_0}{2} \text{tr}(\Sigma_k^{-1} (\boldsymbol{\mu}_k - \boldsymbol{\mu}_0)^T (\boldsymbol{\mu}_k - \boldsymbol{\mu}_0)) \right). \quad (34)$$

698 The required equation we are interested in is (C).

$$\begin{aligned} & \sum_{i=1}^n \sum_{k=1}^K a_{ik} \log(f(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k)) \\ &= \sum_{k=1}^K \left\{ -\sum_{i=1}^n a_{ik} \frac{D \log(2\pi)}{2} - \frac{1}{2} \sum_{k=1}^n a_{ik} \log |\Sigma_k| - \frac{1}{2} \sum_{i=1}^n a_{ik} \text{tr}(\Sigma_k^{-1} (\mathbf{x}_i - \boldsymbol{\mu}_k)^T (\mathbf{x}_i - \boldsymbol{\mu}_k)) \right\} \\ &= \sum_{k=1}^K \left\{ -a_k \frac{D \log(2\pi)}{2} - \frac{1}{2} a_k \log |\Sigma_k| - \frac{1}{2} \text{tr} \left(\Sigma_k^{-1} \sum_{i=1}^n a_{ik} (\mathbf{x}_i - \boldsymbol{\mu}_k)^T (\mathbf{x}_i - \boldsymbol{\mu}_k) \right) \right\}. \end{aligned} \quad (35)$$

699 Now to derive the M-step objective we remove the constant terms and add on the log
700 prior. This leads to

$$\begin{aligned} & \sum_{k=1}^K \left\{ \frac{\nu_0 + D + 2}{2} \log |\Sigma_k| - \frac{1}{2} \text{tr} (\Sigma_k^{-1} S_0^{-1}) - \frac{\lambda_0}{2} \text{tr} (\Sigma_k^{-1} (\boldsymbol{\mu}_k - \boldsymbol{\mu}_0)^T (\boldsymbol{\mu}_k - \boldsymbol{\mu}_0)) \right\} \\ & + \sum_{k=1}^K \left\{ -\frac{1}{2} a_k \log |\Sigma_k| - \frac{1}{2} \text{tr} \left(\Sigma_k^{-1} \sum_{i=1}^n a_{ik} (\mathbf{x}_i - \boldsymbol{\mu}_k)^T (\mathbf{x}_i - \boldsymbol{\mu}_k) \right) \right\}. \end{aligned} \quad (36)$$

701 This can be rewritten as

$$\begin{aligned} & \sum_{k=1}^K \left\{ \frac{\nu_0 + D + 2 + a_k}{2} \log |\Sigma_k| - \frac{1}{2} \text{tr} (\Sigma_k^{-1} S_0^{-1}) - \frac{\lambda_0}{2} \text{tr} (\Sigma_k^{-1} (\boldsymbol{\mu}_k - \boldsymbol{\mu}_0)^T (\boldsymbol{\mu}_k - \boldsymbol{\mu}_0)) \right\} \\ & + \sum_{k=1}^K \left\{ -\frac{1}{2} \text{tr} \left(\Sigma_k^{-1} \sum_{i=1}^n a_{ik} (\mathbf{x}_i - \boldsymbol{\mu}_k)^T (\mathbf{x}_i - \boldsymbol{\mu}_k) \right) \right\}. \end{aligned} \quad (37)$$

702 Now define $\bar{\mathbf{x}}_k = (\sum_{i=1}^n a_{ik} \mathbf{x}_i) / a_k$ and note the following algebraic rearrangements.

$$\begin{aligned} & \sum_{i=1}^n a_{ik} (\mathbf{x}_i - \boldsymbol{\mu}_k)^T (\mathbf{x}_i - \boldsymbol{\mu}_k) \\ & = \sum_{i=1}^n a_{ik} \mathbf{x}_i^T \mathbf{x}_i - \boldsymbol{\mu}_k^T \sum_{i=1}^n a_{ik} \mathbf{x}_i - \left(\sum_{i=1}^n a_{ik} \mathbf{x}_i^T \right) \boldsymbol{\mu}_k + a_k \boldsymbol{\mu}_k^T \boldsymbol{\mu}_k \\ & = \sum_{i=1}^n a_{ik} \mathbf{x}_i^T \mathbf{x}_i - \boldsymbol{\mu}_k^T \sum_{i=1}^n a_{ik} \mathbf{x}_i - \left(\sum_{i=1}^n a_{ik} \mathbf{x}_i^T \right) \boldsymbol{\mu}_k + a_k \boldsymbol{\mu}_k^T \boldsymbol{\mu}_k \\ & = \sum_{i=1}^n a_{ik} \mathbf{x}_i^T \mathbf{x}_i - a_k \boldsymbol{\mu}_k^T \bar{\mathbf{x}}_k - a_k \bar{\mathbf{x}}_k^T \boldsymbol{\mu}_k + a_k \boldsymbol{\mu}_k^T \boldsymbol{\mu}_k \\ & = \sum_{i=1}^n a_{ik} \mathbf{x}_i^T \mathbf{x}_i - a_k \bar{\mathbf{x}}_k^T \bar{\mathbf{x}}_k + a_k (\bar{\mathbf{x}}_k - \boldsymbol{\mu}_k)^T (\bar{\mathbf{x}}_k - \boldsymbol{\mu}_k) \\ & = \sum_{i=1}^n a_{ik} (\mathbf{x}_i - \bar{\mathbf{x}}_k)^T (\mathbf{x}_i - \bar{\mathbf{x}}_k) + a_k (\bar{\mathbf{x}}_k - \boldsymbol{\mu}_k)^T (\bar{\mathbf{x}}_k - \boldsymbol{\mu}_k) \end{aligned} \quad (38)$$

703 This allows us to rewrite equation 37 as

$$\begin{aligned} & \sum_{k=1}^K \left\{ \frac{\nu_0 + D + 2 + a_k}{2} \log |\Sigma_k| - \frac{1}{2} \text{tr} \left(\Sigma_k^{-1} \left(S_0^{-1} + \sum_{i=1}^n a_{ik} (\mathbf{x}_i - \bar{\mathbf{x}}_k)^T (\mathbf{x}_i - \bar{\mathbf{x}}_k) \right) \right) \right\} \\ & + \sum_{k=1}^K \left\{ -\frac{1}{2} \text{tr} (\Sigma_k^{-1} (\lambda_0 (\boldsymbol{\mu}_k - \boldsymbol{\mu}_0)^T (\boldsymbol{\mu}_k - \boldsymbol{\mu}_0) + a_k (\bar{\mathbf{x}}_k - \boldsymbol{\mu}_k)^T (\bar{\mathbf{x}}_k - \boldsymbol{\mu}_k))) \right\} \end{aligned} \quad (39)$$

This can be written as:

$$\sum_{k=1}^K \left\{ \frac{\nu_k + D + 2}{2} \log |\Sigma_k| - \frac{1}{2} \text{tr} (\Sigma_k^{-1} S_k^{-1}) - \frac{1}{2} \text{tr} (\Sigma_k^{-1} (\lambda_k (\boldsymbol{\mu}_k - \mathbf{m}_k)^T (\boldsymbol{\mu}_k - \mathbf{m}_k))) \right\} \quad (40)$$

where,

$$\begin{aligned} \lambda_k &= \lambda_0 + a_k \\ \nu_k &= \nu_0 + a_k \\ \mathbf{m}_k &= \frac{a_k \bar{\mathbf{x}}_k + \lambda_0 \boldsymbol{\mu}_0}{\lambda_k} \\ S_k^{-1} &= S_0^{-1} + \frac{\lambda_0 a_k}{\lambda_k} (\bar{\mathbf{x}}_k - \boldsymbol{\mu}_0)^T (\bar{\mathbf{x}}_k - \boldsymbol{\mu}_0) + \sum_{i=1}^n a_{ik} (\mathbf{x}_i - \bar{\mathbf{x}}_k)^T (\mathbf{x}_i - \bar{\mathbf{x}}_k) \end{aligned} \quad (41)$$

Thus the parameters of the posterior mode are:

$$\begin{aligned} \hat{\boldsymbol{\mu}}_k &= \mathbf{m}_k \\ \hat{\Sigma}_k &= \frac{1}{\nu_k + D + 2} S_k^{-1} \end{aligned} \quad (42)$$

To summarise the EM algorithm, we iterate between the two steps:

E-Step: Given the current parameters compute the values given by equations (28), with formulas provided in equations (8) and (9).

M-Step: Compute

$$\epsilon = \frac{u + b - 1}{(a + b) + (u + v) - 2},$$

and

$$\pi_k = \frac{r_k + \beta_k - 1}{N + \sum \beta_k - K},$$

as well as

$$\bar{\mathbf{x}}_k = \frac{1}{a_k} \left(\sum_{i=1}^n a_{ik} \mathbf{x}_i \right)$$

Compute the MAP estimates given by equations (42). These estimates are then used in the following iteration of the E-step. Iterate until $|Q(\boldsymbol{\theta}|\boldsymbol{\theta}_t) - Q(\boldsymbol{\theta}|\boldsymbol{\theta}_{t-1})| < \delta$ for some pre-specified $\delta > 0$.

5.2 Appendix 2: Derivation of collapsed Gibbs sampler for TAGM model

To derive the Gibbs sampler we write down all the conditional probabilities. Then, exploiting conjugacy, we can marginalise parameters in the model. Recall the total joint probability is the following:

$$\begin{aligned}
 p(\boldsymbol{\theta}, \Theta, X, Z, \Phi) &= p(X, Z, \Phi | \boldsymbol{\theta}, \boldsymbol{\pi}, \epsilon) p(\epsilon | u, v) p(\boldsymbol{\theta} | H) p(\boldsymbol{\pi} | \beta) \\
 &= \prod_{i=1}^n \prod_{k=1}^K (\pi_k ((1 - \epsilon) \mathcal{N}(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k))^{\mathbb{1}(\phi_i=1)} (\epsilon \mathcal{T}(\mathbf{x}_i | \kappa, \mathbf{M}, V))^{\mathbb{1}(\phi_i=0)})^{\mathbb{1}(z_i=k)} \\
 &\quad \cdot \left(\prod_{k=1}^K \mathcal{N} \mathcal{I} \mathcal{W}(H) \right) \cdot \text{Dir}(\beta) \cdot \mathcal{B}(u, v).
 \end{aligned} \tag{43}$$

Suppose we know the hidden latent component allocations z_i and outlier allocations ϕ_i . Then we could sample from the a required normal distribution. The conditional probability of the parameters given the allocations is given by:

$$p(\theta_k | X, Z, \Phi, \theta_{-k}, \beta, u, v, H) \propto p_0(\theta_k) \prod_{i=1}^n N(\mathbf{x}_i | \boldsymbol{\mu}_k, \Sigma_k)^{\mathbb{1}(\phi_i=1)}. \tag{44}$$

The prior is conjugate and so the posterior belongs to the same parametric family as the prior, a NIW distribution, and so the parameters can be updated as follows:

$$\begin{aligned}
 m_k &= \frac{n_k \bar{\mathbf{x}}_k + \lambda_0 \boldsymbol{\mu}_0}{\lambda_k} \\
 \lambda_k &= \lambda_0 + n_k \\
 \nu_k &= \nu_0 + n_k \\
 S_k &= S_0 + \sum_{i: z_i=k, \phi_i=1} (\mathbf{x}_i - \bar{\mathbf{x}})^T (\mathbf{x}_i - \bar{\mathbf{x}}) + \frac{\lambda_0 n_k}{\lambda_k} (\bar{\mathbf{x}} - \boldsymbol{\mu}_0)^T (\bar{\mathbf{x}} - \boldsymbol{\mu}_0),
 \end{aligned} \tag{45}$$

where $n_k = |\{\mathbf{x}_i | z_i = k, \phi_i = 1\}|$. Now we write down the conditional of the component allocations

$$p(z_i = k | X, z_{-i}, \Phi, \theta, \beta, u, v, H) \propto p_0(z_i = k | z_{-i}, \beta) p(\mathbf{x}_i | \mathbf{x}_{-i}, z_{-i}, z_i = k, \Phi, H). \tag{46}$$

The first term in this equation is

$$p_0(z_i = k | z_{-i}, \beta) = \frac{p(z_i = k, z_{-i} | \beta)}{p(z_{-i} | \beta)} = \frac{p(Z | \beta)}{p(z_{-i} | \beta)}. \tag{47}$$

729 To calculate the numerator we proceed by marginalising over $\boldsymbol{\pi}$ as follows

$$p(Z|\beta) = \int p(z|\boldsymbol{\pi})p(\boldsymbol{\pi}|\beta)d\boldsymbol{\pi} = \frac{\Gamma(\beta)}{\Gamma(n+\beta)} \prod_{k=1}^K \frac{\Gamma(n_k + \beta_k)}{\Gamma(\beta_k)}. \quad (48)$$

730 Hence, we arrive at the following probability:

$$p_0(z_i = k|z_{-i}, \beta) = \frac{n_{k \setminus i} + \beta_k}{n + \sum \beta_k - 1}. \quad (49)$$

731 The conditional for the second term of 46 is more tricky. First note the following condi-
732 tional distributions

$$\begin{aligned} \mathbf{x}_i|z_i = k, X_{k \setminus i}, \phi_i = 1, \Phi, z_{-i} &\sim \mathcal{N}(\mathbf{x}_i|\theta_k) \\ \mathbf{x}_i|z_i = k, X_{k \setminus i}, \phi_i = 0, \Phi, z_{-i} &\sim \mathcal{T}(\mathbf{x}_i|\kappa, \mathbf{M}, V), \\ \mathbf{x}_i|z_i = k, X_{k \setminus i}, \phi_i, \Phi, z_{-i} &\sim N(\mathbf{x}_i|\theta_k)^{\mathbf{1}(\phi_i=1)} \mathcal{T}(\mathbf{x}_i|\kappa, \mathbf{M}, V)^{\mathbf{1}(\phi_i=0)}, \end{aligned} \quad (50)$$

733 where we denote $X_{k \setminus i}$ as the observations associated with class k , besides x_i . Now, we
734 first note that:

$$p(\mathbf{x}_i|z_i = k, X_{k \setminus i}, \phi_i, \Phi, H, z_{-i}) = p(\mathbf{x}_i|X_{k \setminus i}, \phi_i, \Phi, H) = \frac{p(\mathbf{x}_i, X_{k \setminus i}|\phi_i, \Phi, H)}{p(X_{k \setminus i}|\phi_i, \Phi, H)}. \quad (51)$$

735 Thus, we find an equation for the numerator, using the fact that terms associated with
736 $\phi_i = 0$ do not depend on k and thus can be absorbed into the normalising constant.

$$p(X_k|\phi_i, \Phi, H) \propto \prod_{i:\phi_i=1} \int p(\mathbf{x}_i|z_i = k, \Phi, H, \theta_k) p(\theta_k|H) d\theta_k. \quad (52)$$

737 This is the marginal likelihood of the data. Thus the ratio in 51 is the posterior predictive
738 which is given by the non-centred T-distribution with formula given by:

$$\mathcal{T}\left(v_k - d + 1, m_k, \frac{(1 + \lambda_k)S_k}{\lambda_k(v_k - d + 1)}\right).$$

739 Thus, we can compute the following:

$$\begin{aligned} p(z_i = k|X, z_{-i}, \Phi, \theta, \beta, u, v, H) &\propto p_0(z_i = k|z_{-i}, \beta) p(\mathbf{x}_i|\mathbf{x}_{-i}, z_{-i}, \Phi, z_i = k, H) \\ &= \frac{n_{k \setminus i} + \beta_k}{n + \sum \beta_k - 1} \mathcal{T}\left(\mathbf{x}_i|v_k - d + 1, m_k, \frac{(1 + \lambda_k)S_k}{\lambda_k(v_k - d + 1)}\right). \end{aligned} \quad (53)$$

740 It remains to compute the conditional for the ϕ_i . By first recalling that ϕ_i is binary we
741 see that

$$p(\phi_i|X, Z, \theta, \beta, u, v, H) \propto p_0(\phi_i) \prod_{i=1}^n N(\mathbf{x}_i|\theta_{z_i})^{\mathbb{1}(\phi_i=1)} T(\mathbf{x}_i|\kappa, M, V)^{\mathbb{1}(\phi_i=0)} \quad (54)$$

742 can be written as

$$\begin{aligned} p(\phi_i = 1|X, Z, \theta, \phi_{-i}, \beta, u, v, H) &\propto p_0(\phi_i = 1|\phi_{-i}, u, v) p(\mathbf{x}_i|\mathbf{x}_{-i}, \phi_i = 1, Z, \theta, \Phi, \beta, u, v, H), \\ p(\phi_i = 0|X, Z, \theta, \phi_{-i}, \beta, u, v, H) &\propto p_0(\phi_i = 0|\phi_{-i}, u, v) p(\mathbf{x}_i|\mathbf{x}_{-i}, \phi_i = 0, Z, \theta, \Phi, \beta, u, v, H). \end{aligned} \quad (55)$$

743 First we need to compute a formula for $p_0(\phi_i|\phi_{-i}, u, v)$. First we see that

$$p_0(\phi_i|\phi_{-i}, u, v) = \frac{p(\Phi|u, v)}{p(\phi_{-i}|u, v)}. \quad (56)$$

744 The numerator can be computed by marginalising over ϵ :

$$p(\Phi|u, v) = \int p(\Phi|\epsilon) p(\epsilon|u, v) d\epsilon. \quad (57)$$

745 We denote $\sum \mathbb{1}(\phi_i = 1) = \tau_1$ and $\sum \mathbb{1}(\phi_i = 0) = \tau_0 = 1 - \tau_1$. Then it is easy to see that

$$\begin{aligned} p(\Phi|u, v) &= \int p(\Phi|\epsilon) p(\epsilon|u, v) d\epsilon \\ &= \frac{1}{B(u, v)} \int (1 - \epsilon)^{\tau_1+v-1} \epsilon^{\tau_0+u-1} d\epsilon \\ &= \frac{B(\tau_0 + u, \tau_1 + v)}{B(u, v)}. \end{aligned} \quad (58)$$

746 Hence,

$$\begin{aligned} p(\phi_i = 1|\phi_{-i}, u, v) &= \frac{B(\tau_0 + u, \tau_1 + v)}{B(u, v)} \cdot \frac{B(u, v)}{B(\tau_0 + u, \tau_1 + v - 1)} \\ &= \frac{\tau_1 + v - 1}{n + u + v - 1}, \end{aligned} \quad (59)$$

747 where $n = \tau_1 + \tau_2$. In general,

$$p(\phi_i = s|\phi_{-i}, u, v) = \frac{\tau_{s \setminus i} + v^s u^{1-s}}{n + u + v - 1}. \quad (60)$$

748 Now we return to computing $p(\mathbf{x}_i|\mathbf{x}_{-i}, Z, \theta, \phi_i = 1, \Phi, \beta, u, v, H)$. First we see that

$$p(\mathbf{x}_i|\mathbf{x}_{-i}, Z, \theta, \phi_i = 1, \Phi, \beta, u, v, H) = \frac{p(X|Z, \theta, \phi_i = 1, \Phi, \beta, u, v, H)}{p(\mathbf{x}_{-i}|Z, \theta, \phi_i = 1, \Phi, \beta, u, v, H)}. \quad (61)$$

Thus if we integrate over the parameters, we would have a ratio of marginal likelihoods giving the posterior predictive which is a non-centred T-distribution:

$$p(\mathbf{x}_i|\mathbf{x}_{-i}, Z, \theta, \phi_i = 1, \Phi, \beta, u, v, H) = \mathcal{T}\left(v_k - d + 1, m_k, \frac{(1 + \lambda_k)S_k}{\lambda_k(v_k - d + 1)}\right). \quad (62)$$

In the other case that $\phi = 0$, we have that

$$p(x_i|x_{-i}, Z, \theta, \phi_i = 0, \Phi, \beta, u, v, H) = \mathcal{T}(x_i|\kappa, \mathbf{M}, V). \quad (63)$$

Thus we can compute:

$$p(\phi_i|X, Z, \theta, \phi_{-i}, \beta, u, v, H) \quad (64)$$

and sample from the required distribution. Thus, we can summarise the collapsed Gibbs sampler as follows:

1. Update the priors with the labelled data
2. For the unlabelled observations, in turn, compute the probability of assigning to each component
3. Sample a label according to this probability
4. Compute the probability of belonging to this class or the outlier component
5. Sample an indicator to a class specific component or the outlier component
6. If we assign to the class specific component update the class specific posterior distribution with the statistics of this observation
7. Update other posteriors as appropriate.
8. Once all unlabelled observations have been assigned, consider the observations sequentially, removing the statistics from the posteriors and then performing steps 2-7. We repeat this process for all unlabelled observations.
9. repeat 7-8 until convergence of the Markov-chain.

The computational bottleneck in the algorithm is computing the posterior updates for the parameters

$$\begin{aligned} m_k &= \frac{n_k \bar{\mathbf{x}}_k + \lambda_0 \boldsymbol{\mu}_0}{\lambda_k} \\ \lambda_k &= \lambda_0 + n_k \\ \nu_k &= \nu_0 + n_k \\ S_k &= S_0 + \sum_{i: z_i=k, \phi_i=1} (\mathbf{x}_i - \bar{\mathbf{x}})^T (\mathbf{x}_i - \bar{\mathbf{x}}) + \frac{\lambda_0 n_k}{\lambda_k} (\bar{\mathbf{x}} - \boldsymbol{\mu}_0)^T (\bar{\mathbf{x}} - \boldsymbol{\mu}_0), \end{aligned} \quad (65)$$

770 We first note that

$$S_k = S_0 + \sum_{i: z_i=k, \phi_i=1} \mathbf{x}_i^T \mathbf{x}_i + \lambda_0 \boldsymbol{\mu}_0^T \boldsymbol{\mu}_0 - \lambda_k \boldsymbol{\mu}_k^T \boldsymbol{\mu}_k \quad (66)$$

771 Let us denote $T = \sum_{i: z_i=k, \phi_i=1} \mathbf{x}_i^T \mathbf{x}_i$. Thus we can derive a set of iterative updates
 772 to speed up computation when adding/removing statistics from clusters. More precisely,
 773 indicating updated posterior parameters by a prime, if we remove statistics of observation i
 774 from cluster k , we see that

$$\begin{aligned} m'_k &= \frac{\lambda_k m_k - \mathbf{x}_i}{\lambda_k - 1} \\ \lambda'_k &= \lambda_k - 1 \\ \nu'_k &= \nu_k - 1 \\ T' &= T - \mathbf{x}_i^T \mathbf{x}_i \\ S'_k &= S_0 + T' + \lambda_0 \boldsymbol{\mu}_0^T \boldsymbol{\mu}_0 - \lambda_k m_k'^T m'_k. \end{aligned} \quad (67)$$

775 Likewise if we add the statistics of observation i to cluster k , we see that

$$\begin{aligned} m'_k &= \frac{\lambda_k m_k + \mathbf{x}_i}{\lambda_k + 1} \\ \lambda'_k &= \lambda_k + 1 \\ \nu'_k &= \nu_k + 1 \\ T' &= T + \mathbf{x}_i^T \mathbf{x}_i \\ S'_k &= S_0 + T' + \lambda_0 \boldsymbol{\mu}_0^T \boldsymbol{\mu}_0 - \lambda_k m_k'^T m'_k. \end{aligned} \quad (68)$$

776 5.3 Appendix 3: Convergence diagnostics of EM algorithm




Figure 14: Plot of the log-posterior at each iteration of the EM algorithm to demonstrate monotonicity and convergence

777 5.4 Appendix 4: Trace plots for assessing MCMC convergence




Figure 15: Trace plots of the number of proteins allocated to the known components in each of 6 parallel MCMC runs. Chain 4 is discarded because of lack of convergence. 600 samples are retained from remaining chains and pooled.

5.5 Appendix 5: F1 t-tests

	SVM	KNN	MAP
KNN	2.7E-03		
MAP	3.3E-02	3.4E-01	
MCMC	3.4E-01	3.3E-02	2.3E-01

Table 2: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Drosophila dataset

	SVM	KNN	MAP
KNN	1.2E-02		
MAP	2.7E-01	1.5E-01	
MCMC	4.9E-01	1.9E-03	1.1E-01

Table 3: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Chicken DT40 dataset

	SVM	KNN	MAP
KNN	1.0E+00		
MAP	1.0E+00	1.0E+00	
MCMC	3.3E-01	6.0E-02	1.1E-05

Table 4: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the mouse dataset

	SVM	KNN	MAP
KNN	1.4E-35		
MAP	3.3E-06	6.7E-21	
MCMC	8.0E-59	3.2E-91	2.4E-70

Table 5: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the HeLa dataset

	SVM	KNN	MAP
KNN	1.3E-02		
MAP	4.3E-04	3.3E-09	
MCMC	5.8E-01	3.5E-03	3.1E-03

Table 6: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the U2-OS dataset

	SVM	KNN	MAP
KNN	2.2E-08		
MAP	1.0E-34	6.8E-14	
MCMC	7.4E-05	5.3E-02	1.0E-20

Table 7: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the HeLa wild (Hirst et al.) dataset

	SVM	KNN	MAP
KNN	5.3E-02		
MAP	1.7E-23	7.9E-27	
MCMC	9.1E-02	5.8E-04	1.8E-19

Table 8: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the HeLa KO1 (Hirst et al.) dataset

	SVM	KNN	MAP
KNN	1.3E-01		
MAP	1.1E-55	1.1E-55	
MCMC	1.0E-18	6.3E-22	2.0E-26

Table 9: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the HeLa KO2 (Hirst et al.) dataset

	SVM	KNN	MAP
KNN	9.6E-02		
MAP	4.1E-07	1.1E-09	
MCMC	2.8E-27	1.0E-28	6.3E-10

Table 10: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts Mock 24hpi dataset

	SVM	KNN	MAP
KNN	6.6E-07		
MAP	1.3E-10	2.0E-01	
MCMC	1.6E-05	2.0E-01	6.2E-03

Table 11: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts Mock 48hpi dataset

	SVM	KNN	MAP
KNN	3.9E-03		
MAP	9.5E-01	8.6E-03	
MCMC	6.4E-02	3.0E-01	8.6E-02

Table 12: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts Mock 72hpi dataset

	SVM	KNN	MAP
KNN	8.6E-03		
MAP	1.1E-02	8.6E-01	
MCMC	3.7E-06	1.6E-02	3.3E-02

Table 13: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts Mock 96hpi dataset

	SVM	KNN	MAP
KNN	1.9E-23		
MAP	1.4E-02	2.3E-34	
MCMC	3.8E-07	1.6E-81	2.0E-02

Table 14: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts Mock 120hpi dataset

	SVM	KNN	MAP
KNN	4.6E-01		
MAP	2.6E-05	1.7E-04	
MCMC	1.7E-04	1.3E-03	5.5E-01

Table 15: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts HCMV 24hpi dataset

	SVM	KNN	MAP
KNN	1.0E-02		
MAP	4.6E-01	1.5E-03	
MCMC	1.2E-02	7.3E-01	1.5E-03

Table 16: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts HCMV 48hpi dataset

	SVM	KNN	MAP
KNN	5.5E-02		
MAP	9.5E-06	3.4E-02	
MCMC	1.1E-01	6.2E-01	6.4E-03

Table 17: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts HCMV 72hpi dataset

	SVM	KNN	MAP
KNN	2.8E-01		
MAP	2.6E-09	7.2E-08	
MCMC	4.2E-10	5.6E-09	5.7E-01

Table 18: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts HCMV 96hpi dataset

	SVM	KNN	MAP
KNN	2.3E-04		
MAP	7.1E-04	3.8E-10	
MCMC	1.4E-01	5.7E-02	6.0E-05

Table 19: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the Primary Fibroblasts HCMV 120hpi dataset

	SVM	KNN	MAP
KNN	6.7E-06		
MAP	6.3E-05	4.4E-01	
MCMC	4.4E-01	6.7E-06	8.3E-05

Table 20: Adjusted P-values for pairwise T-tests for Macro F-1 score classifier evaluation on the E14TG2a dataset

5.6 Appendix 6: Quadratic loss t-tests

	SVM	KNN	MAP
KNN	5.9E-13		
MAP	1.1E-04	9.6E-124	
MCMC	2.2E-23	3.3E-58	5.9E-171

Table 21: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Drosophila dataset

	SVM	KNN	MAP
KNN	3.2E-08		
MAP	1.7E-26	1.3E-128	
MCMC	4.2E-13	8.8E-37	7.0E-135

Table 22: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Chicken DT40 dataset

	SVM	KNN	MAP
KNN	5.5E-14		
MAP	3.0E-25	6.3E-128	
MCMC	7.4E-26	1.7E-129	1.6E-14

Table 23: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the mouse dataset

	SVM	KNN	MAP
KNN	1.2E-02		
MAP	9.4E-07	7.4E-86	
MCMC	5.5E-08	2.7E-89	2.4E-12

Table 24: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the HeLa dataset

	SVM	KNN	MAP
KNN	6.8E-02		
MAP	7.4E-17	1.1E-73	
MCMC	1.4E-20	6.7E-81	8.3E-41

Table 25: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the U2-OS dataset

	SVM	KNN	MAP
KNN	2.3E-92		
MAP	9.0E-13	2.4E-83	
MCMC	6.6E-19	3.0E-81	1.1E-01

Table 26: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the HeLa wild (Hirst et al.) dataset

	SVM	KNN	MAP
KNN	5.2E-97		
MAP	1.4E-02	1.2E-90	
MCMC	2.3E-09	7.0E-95	2.2E-02

Table 27: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the HeLa KO1 (Hirst et al.) dataset

	SVM	KNN	MAP
KNN	8.9E-93		
MAP	3.1E-01	8.1E-91	
MCMC	9.0E-06	1.5E-83	8.9E-05

Table 28: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the HeLa KO2 (Hirst et al.) dataset

	SVM	KNN	MAP
KNN	6.1E-13		
MAP	1.4E-18	4.4E-81	
MCMC	3.2E-18	7.2E-77	5.9E-03

Table 29: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts Mock 24hpi dataset

	SVM	KNN	MAP
KNN	6.1E-18		
MAP	3.6E-24	2.2E-57	
MCMC	1.4E-24	3.6E-61	3.6E-04

Table 30: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts Mock 48hpi dataset

	SVM	KNN	MAP
KNN	1.2E-15		
MAP	4.5E-23	2.5E-89	
MCMC	4.2E-23	5.1E-91	4.4E-01

Table 31: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts Mock 72hpi dataset

	SVM	KNN	MAP
KNN	1.8E-13		
MAP	1.4E-20	3.6E-126	
MCMC	5.0E-20	1.5E-109	5.3E-07

Table 32: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts Mock 96hpi dataset

	SVM	KNN	MAP
KNN	6.7E-14		
MAP	1.0E-19	2.6E-45	
MCMC	8.0E-20	2.4E-45	2.5E-02

Table 33: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts Mock 120hpi dataset

	SVM	KNN	MAP
KNN	6.0E-22		
MAP	2.8E-27	6.4E-53	
MCMC	1.4E-27	1.5E-56	3.0E-03

Table 34: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts HCMV 24hpi dataset

	SVM	KNN	MAP
KNN	1.9E-26		
MAP	1.3E-33	2.7E-84	
MCMC	1.3E-33	2.7E-84	6.0E-01

Table 35: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts HCMV 48hpi dataset

	SVM	KNN	MAP
KNN	6.3E-20		
MAP	1.9E-25	2.7E-57	
MCMC	1.2E-25	3.4E-58	1.5E-02

Table 36: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts HCMV 72hpi dataset

	SVM	KNN	MAP
KNN	1.7E-25		
MAP	9.3E-32	1.9E-56	
MCMC	9.3E-32	1.2E-54	7.1E-01

Table 37: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts HCMV 96hpi dataset

	SVM	KNN	MAP
KNN	6.5E-25		
MAP	5.3E-32	1.1E-71	
MCMC	7.1E-32	8.4E-71	5.7E-02

Table 38: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the Primary Fibroblasts HCMV 120hpi dataset

	SVM	KNN	MAP
KNN	4.7E-04		
MAP	4.7E-21	1.5E-103	
MCMC	3.3E-12	1.8E-57	1.3E-137

Table 39: Adjusted P-values for pairwise T-tests for Quadratic Loss classifier evaluation on the E14TG2a dataset

780 **5.7 Appendix 7: GO enrichment analysis figures**




Figure 16: Gene Ontology over representation analysis on outlier proteins - that is proteins allocated with less than probability 0.95. We analyse the enrichment of terms in the cellular compartment, biological process, and molecular function ontologies. We display the top 10 significant results in the dotplots.




Figure 17: A heatmap representation of a contingency table comparing allocation produced by MCMC and MAP methods with posterior probability threshold set at 0.99 for both methods. The scale ranges from 0 to 1 with values indicating the proportion of assigned proteins to that sub-cellular location. Values along the diagonal represent agreement between classifiers whilst other values represent disagreement. The allocations of proteins by both methods are in strong agreement.

References

- Banfield, J. D. et al. (1993). Model-based gaussian and non-gaussian clustering. *Biometrics*, pages 803–821.
- Beltran, P. M. J. et al. (2016). A portrait of the human organelle proteome in space and time during cytomegalovirus infection. *Cell systems*, **3**(4), 361–373.
- Benjamini, Y. et al. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the royal statistical society. Series B (Methodological)*, pages 289–300.
- Boyle, E. I. et al. (2004). GO::TermFinder – open source software for accessing gene ontology information and finding significantly enriched gene ontology terms associated with a list of genes. *Bioinformatics*, **20**(18), 3710–3715.
- Breckels, L. M. et al. (2013). The effect of organelle discovery upon sub-cellular protein localisation. *Journal of proteomics*, **88**, 129–140.
- Breckels, L. M. et al. (2016a). A bioconductor workflow for processing and analysing spatial proteomics data. *F1000Research*, **5**.
- Breckels, L. M. et al. (2016b). Learning from heterogeneous data sources: an application in spatial proteomics. *PLoS computational biology*, **12**(5), e1004920.
- Brooks, S. P. et al. (1998). General methods for monitoring convergence of iterative simulations. *Journal of computational and graphical statistics*, **7**(4), 434–455.
- Choi, H. et al. (2010). Analysis of protein complexes through model-based biclustering of label-free quantitative ap-ms data. *Molecular Systems Biology*, **6**(1), 385.
- Christoforou, A. et al. (2016). A draft map of the mouse pluripotent stem cell spatial proteome. *Nature communications*, **7**, 9992.
- Cody, N. A. et al. (2013). The many functions of mrna localization during normal development and disease: from pillar to post. *Wiley Interdisciplinary Reviews: Developmental Biology*, **2**(6), 781–796.
- Cooke, E. J. et al. (2011). Bayesian hierarchical clustering for microarray time series data with replicates and outlier measurements. *BMC bioinformatics*, **12**(1), 399.
- Coretto, P. et al. (2016). Robust improper maximum likelihood: tuning, computation, and a comparison with other methods for robust gaussian clustering. *Journal of the American Statistical Association*, **111**(516), 1648–1659.
- De Duve, C. et al. (1981). A short history of tissue fractionation. *The Journal of cell biology*, **91**(3), 293.
- De Matteis, M. A. et al. (2011). Mendelian disorders of membrane trafficking. *New England Journal of Medicine*, **365**(10), 927–938.

817 Dempster, A. P. et al. (1977). Maximum likelihood from incomplete data via the em algo-
818 rithm. *Journal of the royal statistical society. Series B (methodological)*, pages 1–38.

819 Dunkley, T. P. et al. (2004). Localization of organelle proteins by isotope tagging (lopit).
820 *Molecular & Cellular Proteomics*, **3**(11), 1128–1134.

821 Dunkley, T. P. et al. (2006). Mapping the arabidopsis organelle proteome. *Proceedings of*
822 *the National Academy of Sciences*, **103**(17), 6518–6523.

823 Foster, L. J. et al. (2006). A mammalian organelle map by protein correlation profiling. *Cell*,
824 **125**(1), 187–199.

825 Fraley, C. et al. (2005). Bayesian regularization for normal mixture estimation and model-
826 based clustering. Technical report, Washington Univ Seattle Dept of Statistics.

827 Fraley, C. et al. (2007). Bayesian regularization for normal mixture estimation and model-
828 based clustering. *Journal of Classification*, **24**(2), 155–181.

829 Gatto, L. et al. (2012). Msnbase - an r/bioconductor package for isobaric tagged mass
830 spectrometry data visualization, processing and quantitation. *Bioinformatics*, **28**, 288–
831 289.

832 Gatto, L. et al. (2010). Organelle proteomics experimental designs and analysis. *Proteomics*,
833 **10**(22), 3957–3969.

834 Gatto, L. et al. (2014a). A foundation for reliable spatial proteomics data analysis. *Molecular*
835 *& Cellular Proteomics*, pages mcp–M113.

836 Gatto, L. et al. (2014b). Mass-spectrometry based spatial proteomics data analysis using
837 proloc and prolocdata. *Bioinformatics*.

838 Gelman, A. et al. (1992). Inference from iterative simulation using multiple sequences.
839 *Statistical science*, pages 457–472.

840 Gelman, A. et al. (1995). *Bayesian Data Analysis*. Chapman & Hall, London.

841 Gentleman, R. C. et al. (2004). Bioconductor: open software development for computational
842 biology and bioinformatics. *Genome biology*, **5**(10), R80.

843 Gibson, T. J. (2009). Cell regulation: determined to signal discrete cooperation. *Trends in*
844 *biochemical sciences*, **34**(10), 471–482.

845 Gneiting, T. et al. (2007). Strictly proper scoring rules, prediction, and estimation. *Journal*
846 *of the American Statistical Association*, **102**(477), 359–378.

847 Groen, A. J. et al. (2014). Identification of trans-golgi network proteins in arabidopsis
848 thaliana root tissue. *Journal of proteome research*, **13**(2), 763–776.

849 Hall, S. L. et al. (2009). The organelle proteome of the dt40 lymphocyte cell line. *Molecular*
850 *& Cellular Proteomics*, **8**(6), 1295–1305.

851 Hazimeh, H. et al. (2015). Axiomatic analysis of smoothing methods in language models
852 for pseudo-relevance feedback. *Proceedings of the 2015 International Conference on The*
853 *Theory of Information Retrieval*, pages 141–150.

854 He, H. et al. (2009). Learning from imbalanced data. *IEEE Transactions on knowledge and*
855 *data engineering*, **21**(9), 1263–1284.

856 Heard, W. et al. (2015). Identification of regulatory and cargo proteins of endosomal and
857 secretory pathways in arabidopsis thaliana by proteomic dissection. *Molecular & Cellular*
858 *Proteomics*, **14**(7), 1796–1813.

859 Hennig, C. (2004). Breakdown points for maximum likelihood estimators of location-scale
860 mixtures. *Annals of Statistics*, pages 1313–1340.

861 Hirst, J. et al. (2018). Role of the ap-5 adaptor protein complex in late endosome-to-golgi
862 retrieval. *PLoS biology*, **16**(1), e2004411.

863 Hsu, C.-w. et al. (2010). A practical guide to support vector classification.

864 Huber, W. et al. (2015). Orchestrating high-throughput genomic analysis with bioconductor.
865 *Nature methods*, **12**(2), 115.

866 Itzhak, D. N. et al. (2016). Global, quantitative and dynamic mapping of protein subcellular
867 localization. *Elife*, **5**, e16950.

868 Jeffery, C. J. (2009). Moonlighting proteins - an update. *Molecular BioSystems*, **5**(4), 345–
869 350.

870 Kau, T. R. et al. (2004). Nuclear transport and cancer: from mechanism to intervention.
871 *Nature Reviews Cancer*, **4**(2), 106–117.

872 Kirk, P. et al. (2015). Systems biology (un) certainties. *Science*, **350**(6259), 386–388.

873 Kirk, P. D. et al. (2016). Retroviruses integrate into a shared, non-palindromic dna motif.
874 *Nature microbiology*, **2**, 16212.

875 Latorre, I. J. et al. (2005). Viral oncoprotein-induced mislocalization of select pdz proteins
876 disrupts tight junctions and causes polarity defects in epithelial cells. *Journal of cell*
877 *science*, **118**(18), 4283–4293.

878 Laurila, K. et al. (2009). Prediction of disease-related mutations affecting protein localiza-
879 tion. *BMC genomics*, **10**(1), 122.

880 Liley, J. et al. (2017). A method for identifying genetic heterogeneity within phenotypically
881 defined disease subgroups. *Nature genetics*, **49**(2), 310.

882 Lönnberg, T. et al. (2017). Single-cell rna-seq and computational analysis using temporal
883 mixture modeling resolves th1/tfh fate bifurcation in malaria. *Science Immunology*, **2**(9).

884 Luheshi, L. M. et al. (2008). Protein misfolding and disease: from the test tube to the
885 organism. *Current opinion in chemical biology*, **12**(1), 25–31.

886 Manning, C. D. et al. (2008). *Introduction to Information Retrieval*. Cambridge University
887 Press, New York, NY, USA.

888 McAlister, G. C. et al. (2014). Multinotch ms3 enables accurate, sensitive, and multiplexed
889 detection of differential expression across cancer cell line proteomes. *Analytical chemistry*,
890 **86**(14), 7150–7158.

891 Meyer, D. et al. (2017). R-package e1071.

892 Mulvey, C. M. et al. (2017). Using hyperLOPIT to perform high-resolution mapping of the
893 spatial proteome. *Nature Protocols*, **12**(6), 1110–1135.

894 Murphy, K. P. (2007). Conjugate bayesian analysis of the gaussian distribution. *Technical*
895 *Report*, **1**, 16.

896 Murphy, K. P. (2012). *Machine learning: a probabilistic perspective*.

897 Nikolovski, N. et al. (2012). Putative glycosyltransferases and other plant golgi apparatus
898 proteins are revealed by lopit proteomics. *Plant physiology*, **160**(2), 1037–1051.

899 Ohta, S. et al. (2010). The protein composition of mitotic chromosomes determined using
900 multiclassifier combinatorial proteomics. *Cell*, **142**(5), 810–821.

901 Olkkonen, V. M. et al. (2006). When intracellular logistics fails-genetic defects in membrane
902 trafficking. *Journal of cell science*, **119**(24), 5031–5045.

903 Parsons, H. et al. (2014). Separation of the plant golgi apparatus and endoplasmic reticulum
904 by free-flow electrophoresis. *Methods in molecular biology (Clifton, NJ)*, **1072**, 527.

905 R Core Team (2017). *R: A Language and Environment for Statistical Computing*. R Foun-
906 dation for Statistical Computing, Vienna, Austria.

907 Rodriguez, J. A. et al. (2004). Cytoplasmic mislocalization of brcal caused by cancer-
908 associated mutations in the brc domain. *Experimental cell research*, **293**(1), 14–21.

909 Sadowski, P. G. et al. (2006). Quantitative proteomic approach to study subcellular local-
910 ization of membrane proteins. *Nature protocols*, **1**(4), 1778–1789.

911 Shannon, C. E. (1948). A mathematical theory of communication. *The Bell System Technical*
912 *Journal*, **27**(3), 379–423.

913 Shin, S. J. et al. (2013). Unexpected gain of function for the scaffolding protein plectin due
914 to mislocalization in pancreatic cancer. *Proceedings of the National Academy of Sciences*,
915 **110**(48), 19414–19419.

916 Siljee, J. E. et al. (2018). Subcellular localization of MC4R with ADCY3 at neuronal primary
917 cilia underlies a common pathway for genetic predisposition to obesity. *Nat Genet*.

918 Tan, D. J. et al. (2009). Mapping organelle proteins and protein complexes in drosophila
919 melanogaster. *Journal of proteome research*, **8**(6), 2667–2678.

920 Tardif, M. et al. (2012). Predalgo: a new subcellular localization prediction tool dedicated
921 to green algae. *Molecular biology and evolution*, **29**(12), 3625–3639.

922 Thul, P. J. et al. (2017). A subcellular map of the human proteome. *Science*.

923 Ting, L. et al. (2011). Ms3 eliminates ratio distortion in isobaric multiplexed quantitative
924 proteomics. *Nature methods*, **8**(11), 937.

925 Valcarce, D. et al. (2016). Additive smoothing for relevance-based language modelling of rec-
926 ommender systems. *Proceedings of the 4th Spanish Conference on Information Retrieval*,
927 pages 1–8.

928 Yu, G. et al. (2012). clusterProfiler: an R package for comparing biological themes among
929 gene clusters. *Omics: a journal of integrative biology*, **16**(5), 284–287.